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The use of vaccines has led to the effective eradication of several human diseases which were 
once epidemic such as smallpox and polio. Vaccines have also dramatically decreased the 
incidence of other diseases including rabies, mumps, and measles. A common theme to these 
diseases is that their etiological pathogens are viruses. In general, it has proven to be a much 
more challenging task to develop effective vaccines against bacterial pathogens. The field of 
bacterial vaccinology has seen success in recent decades with the development of 
glycoconjugate vaccines. A canonical glycoconjugate vaccine uses polysaccharides isolated from 
bacterial pathogens and chemically conjugates them to strong protein antigens, thus allowing 
the immune system to generate a robust and long lasting immune response against a 
component of the pathogen that is an ideal target for immune system. This approach has been 
very successful against some bacterial pathogens including Heamophilus influenzae, 
Streptococcus pneumoniae, and Salmonella enterica. However, the semi-synthetic process for 
making these glycoconjugates is lengthy, requiring several rounds of purification before and 
after conjugation chemistry links protein to polysaccharide.  
 This work will discuss alternative wholly biosynthetic processes for the creation of 
glycoconjugate vaccines. I have done preliminary work engineering the glycobiology of 
Escherichia coli to display azide-linked sugars on lipid-linked oligosaccharides with the overall 
 goal of performing in vivo N-linked protein glycosylation to create glycoprotein vaccines that 
can be functionalized through well-characterized bioorthogonal chemistry. I was able to 
observe the presence of these azide-linked sugars on the outer membrane of E. coli by 
fluorescence based screening in a flow cytometer. Additionally, I have leveraged the use of 
recombinant outer membrane vesicles (OMVs) combined with in vivo and in vitro bacterial N-
linked glycosylation to formulate new glycoconjugate vaccines against the bacterial pathogen 
Francisella tularensis. The presence of these glycoproteins in and on the OMVs was verified 
through Western blotting, proteinase protection assays, and density gradient 
ultracentrifugation.  
  I have also formulated a non-canonical glycoconjugate vaccine by producing OMVs 
coated in the common bacterial extra-cellular polysaccharide poly-N-acetylglucosamine 
(PNAG). I have shown that these PNAG OMVs are able to elicit a strong, class-switched glycan-
specific antibody response against PNAG in mice. Mice vaccinated with these PNAG OMVs are 
partially protected against lethal challenge with Staphylococcus aureus (8/16 survivors in PNAG 
OMV immunized mice as compared to 3/16 survivors in PBS control mice). I have also shown 
that sera from mice immunized with PNAG OMVs has bactericidal activity against the 
attenuated strain F. tularensis LVS, suggesting mice immunized with PNAG OMVs may be 
protected from a wide range of pathogens. These studies provide several routes for novel 
formulation of glycoconjugate vaccines against bacterial pathogens. 
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CHAPTER 1 
INTRODUCTION: GLYCOBIOLOGY AND ITS IMPLICATION FOR VACCINE DEVELOPMENT 
Introduction 
Vaccines are recognized as one of the most significant advances in medical history.  
They have led to the eradication of several diseases in areas where they were once endemic.  
Despite these great strides, effective vaccines against a variety of bacterial pathogens remain 
elusive[1].  The advancement of biochemical and genetic engineering techniques led to 
development of targeted subunit vaccines that contain a minimal subset of pathogen derived 
biomolecules[2]. Of these subunit vaccines, glycoconjugate subunit vaccines containing a 
pathogen sourced oligosaccharide antigen chemically conjugated to an adjuvant carrier have 
recently risen to prominence as vaccine candidates against bacterial pathogens[3-5].  
Unfortunately, these glycoconjugate vaccines are often difficult to produce or fail to elicit a 
protective immune response[6].  There is a clear need for better ways of formulating and 
producing more effective glycoconjugate vaccines. 
The discovery that the bacterium Campylobacter jejuni is capable of producing N-linked 
glycoproteins caused an explosion in the field of prokaryotic glycobiology and subsequent 
development of new vaccine production technologies[7].  One of the biggest boons to this 
endeavor was the functional transfer of the C. jejuni protein glycosylation locus (pgl) into 
Escherichia coli[8].  This recombinant pathway can glycosylate many different proteins with a 
wide variety of oligosaccharides in an easy to culture, and genetically tractable, laboratory 
strain of bacteria[9-11].  Additionally, this reaction has been successfully reconstituted in vitro, 
allowing for cell free production of glycoproteins from recombinant bacterial source[12].  The 
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three different components of the canonical bacterial N-linked protein glycosylation reaction 
are the target protein to be glycosylated, the lipid-linked oligosaccharide (LLO), and the 
oligosaccharyltransferase (OST).  By supplying these components in vivo or in vitro, it is possible 
to efficiently produce N-linked glycoproteins that contain oligosaccharide antigens from 
different pathogens. In this work, I will discuss engineering bacterial glycobiology to produce 
different LLO subunits to be used as substrates in N-linked glycosylation reactions both in vivo 
and in vitro with the aim of formulating new vaccine candidates.  
  It has previously been shown by the DeLisa Research Group and others that outer 
membrane vesicles (OMVs) from Gram-negative bacteria can elicit a strong antigen specific 
immune response to protein and oligosaccharide antigens present in, and displayed on, OMVs 
[13-16].  These observations provide an alternative approach to formulating glycoconjugate 
vaccines. Whereas traditional approaches require the conjugation of an oligosaccharide antigen 
to a carrier protein, we have observed a strong protective immune response to recombinant 
oligosaccharide antigens displayed on OMVs. Fortunately, purification of OMVs is relatively 
simple when compared to purification of semisynthetic or biosynthetic glycoproteins. 
Additionally, OMVs are strong stimulators of the innate immune system, potentially making the 
immune response stimulated by them more protective and longer lasting than the response 
generated by traditional glycoconjugates[17-20].  These features make recombinant OMVs an 
attractive platform for vaccine development.   In this work, we discuss how recombinant 
OMVs produced from a hypervesiculating strain of E. coli engineered to produce the bacterial 
polysaccharide antigen poly-N-acetylglucosamine (PNAG) protect mice against lethal 
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challenge with Staphylococcus aureus and PNAG specific antibodies produced by those mice 
have in vitro bactericidal activity against Francisella tularensis LVS. 
 
Bacterial Glycobiology  
Bacterial glycobiology is a field that has existed since the early days of bacteriology. 
When Hans Gram first stained the peptidoglycan of bacterial cells in a heterogeneous sample, a 
fundamental classification of bacterial species based on their divergent membrane structure 
and underlying glycobiology became apparent. Bacterial glycobiology has since led to further 
understanding of bacterial components from peptidoglycan common in all species to the more 
esoteric capsular polysaccharides of Gram-positive species and the lipopolysaccharides (LPS) 
produced by Gram-negative bacteria. Investigation into these extracellular polysaccharides has 
led to a better understanding of bacterial carbohydrate metabolism, environmental 
colonization, and host-pathogen interactions. In this introduction, I will briefly discuss the 
metabolism of glycobiology and how bacteria use sugars as both sword and shield against their 
environments.   
In the world of carbohydrate catabolism, glucose is king. In metabolic networks, it is the 
entry point of the glycolysis pathway, one of the most ancient and ubiquitous of all metabolic 
pathways. Bacteria like E. coli have evolved to make use of this pathway and can transport 
glucose into cells using the phosphotransferase system (PTS). These transporters are so named 
because they phosphorylate their substrates as the substrates are being transported into the 
cell. This phosphorylation primes the glucose molecule for entry into the glycolysis pathway and 
prevents its subsequent diffusion out of the cell.  One glucose molecule is broken down during 
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glycolysis into two pyruvate molecules, generating two adenosine triphosphates (ATPs) and two 
reduced nicotinamide adenine dinucleotides (NADHs) to be used as energetic currency in other 
cellular processes. This catabolic pathway is always necessary, and often sufficient, for the 
energy requirements of bacteria.  In the case of the laboratory strain Escherichia coli K-12, a 
facultative aerobe capable of catabolizing a wide range of substrates, glucose and glycolysis is 
so preferred that the presence of glucose serves as a global repressor for other catabolic 
pathways. In a phenomenon termed the "glucose effect", if there is enough glucose being 
transported through the PTS, E. coli will not use any other substrate as an energy source. It will 
even eschew the much more efficient citric acid cycle and subsequent oxidative 
phosphorylation, which can produce approximately 36 ATPs per glucose molecule. Additionally, 
this catabolite repression keeps the metabolism of the cell balanced toward anabolic processes, 
allowing for rapid growth and accumulation of biomass. In contrast, as the catabolic pathways 
tend to converge at the metabolic nodes associated with the early steps of glycolysis, the 
anabolic pathways tend to diverge from these same few metabolic nodes.  
Different anabolic carbohydrate products can serve a wide variety of functions in a 
bacterial cell such as integral structural components, protective barriers against diffusion or 
attack, colonization of different environments, and modulation of host-specific immune 
responses. A major node in the metabolic network of these anabolic pathways is the metabolite 
N-acetylglucosamine (GlcNAc). The biosynthetic pathway of GlcNAc in E. coli begins with the 
synthesis of glucosamine-6-P (GlcN-6-P) from intracellular pools of the glycolysis metabolite 
fructose-6-P and the amino acid glutamine via the enzyme GlmS. The activated GlcN-6-P is then 
isomerized by GlmM into GlcN-1-P. The next two steps in the process are catalyzed by the 
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enzyme GlmU, a protein comprised of two separate functional domains. The C-terminal domain 
of GlmU catalyzes the addition of the acetyl group onto the C1 amine from acetyl-CoA onto 
GlcN-1-P, forming GlcNAc-1-P, while the N-terminal domain catalyzes the addition of uridine 
diphosphate (UDP) from uridine triphosphate (UTP) forming GlcNAc-UDP. This activated form of 
GlcNAc funnels directly into the production of peptidoglycan, polysaccharides, and glycolipids.  
If E. coli is not in an environment where glucose is plentiful, a plethora of metabolic 
pathways become active as the cell begins to evaluate its environment for alternative growth 
substrates. The previously discussed acetylated hexosamine, GlcNAc, is one such substrate 
capable of sustaining growth in E. coli. As GlcNAc is a major component of the rigid structural 
material peptidoglycan, it is available for use every time a cell must break down peptidoglycan 
prior to undergoing division. When peptidoglycan in the cell wall is degraded, subunits are 
transported into the cell via the permease AmpG and broken down into its constituents by 
AmpD, releasing free cytosolic GlcNAc. The free GlcNAc is then phosphorylated by NagK into 
GlcNAc-6-P, whereupon it can enter the biosynthetic pathway as though it had been produced 
by GlmS. All the proteins involved in the recycling of GlcNAc from peptidoglycan are expressed 
constitutively. However, when the glucose PTS becomes less active as glucose is depleted in the 
environment and extracellular concentrations of GlcNAc are high enough to warrant its use as 
an energy source, the nagEBACD catabolic operon becomes active.  The nagE gene in this 
operon codes for a GlcNAc PTS that allows the cell to efficiently transport and phosphorylate 
extracellular GlcNAc to form GlcNAc-6-P. The enzymes NagA and NagB from this operon are 
then able to funnel GlcNAc-6-P into glycolysis by converting it to fructose-6-P through 
deacetylation and deaminization, respectively. The metabolic balance between anabolism and 
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catabolism is partially maintained by the transcription factor NagC, which acts as a repressor for 
the nagEBACD operon when GlcN-6-P levels are low in the cell. As GlcN-6-P levels rise within 
the cell, not only does NagC repression of the nagEBACD operon lessen, but NagC also acts an 
activator of transcription for the GlmS and GlmU proteins in the anabolic pathways for GlcNAc. 
This simultaneous transcription of the catabolic nagEBACD and the anabolic glmUS operons 
seems to create a futile cycle. This futile cycle is avoided by post-translational modification of 
the isomerase GlmM, which is only active when it is phosphorylated under conditions that are 
favorable for growth. It is this enzyme which acts to direct flux of GlcNAc pathway toward 
either catabolism and fructose-6-P or anabolism and UDP-GlcNAc based on the conditions 
within the cell. If GlcNAc is indeed being shunted toward anabolic pathways, it is likely fated to 
end up in either peptidoglycan or LPS. Alternatively, it can be acted upon by a variety of 
epimerases which can change the identity of the hexose component (i.e. from UDP-GlcNAc to 
UDP-ManNAc) before being used as a substrate for a glycosyl transferase.  
 Peptidoglycan and LPS synthesis in E. coli begins on the inner leaflet of the cytoplasmic 
membrane. Undecaprenyl pyrophosphate (UPP), or bactoprenol, is a common lipid carrier for 
carbohydrates in bacteria. Activated sugars such as UDP-GlcNAc are added to it by 
glycosyltransferases which function in a processive manner to construct carbohydrate 
oligomers, also known as glycans. Once these glycans are fully assembled, they can be 
recognized by specific flippases which flip the lipid-linked oligosaccharide (LLO) so that the 
oligosaccharide portion is facing the periplasm. Once flipped, the glycan, or glycopeptide, 
conjugated lipid can be used in either peptidoglycan synthesis or the O-antigen component of 
LPS.  
7 
 
 The LPS of Gram-negative bacteria consist of three major components: a hexa-acylated 
disaccharide of keto-deoxyoctulosonate (lipid A), a highly-conserved oligosaccharide (inner and 
outer cores), and a repeating oligosaccharide subunit (O-antigen). Lipid A is a strong stimulator 
of the innate immune system due to its ability to trigger an inflammatory response through the 
activation of TLR4, earning it the name endotoxin. The O-antigen structure can vary widely, 
even among the same species of bacteria, adding to the many serotypes within a bacterial 
species.  Though most laboratory strains of E. coli lack the ability to produce an O-antigen due a 
deletion in the rfb gene cluster, they can still produce Lipid A conjugated to a “core 
oligosaccharide” which is synthesized and transported to the pathway through a different 
mechanism[21]. Restoration of O-antigen synthesis can be achieved by supplying the missing E. 
coli genes.  Interestingly, if an exogenous O-antigen biosynthetic pathway from a different 
Gram-negative species is transformed into an E. coli strain deficient in O-antigen synthesis, it 
will produce an O-antigen with a structure that is highly similar to the donor species [9]. The 
glycan subunit built on UPP in the cytoplasm by glycosyltransferases gets flipped to the 
periplasm and acted on by the polymerase Wzy which creates linear polymers of varying length. 
The polymers of various length are then conjugated onto lipid A by the WaaL ligase before the 
mature LPS molecule is transported to the outer membrane where it decorates the cell surface.  
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Figure 1.1: N-acetylglucosamine (GlcNAc) metabolism in E. coli. Metabolic scheme showing 
the metabolism of glucosamine in a typical laboratory strain of E. coli. The figure is divided into 
the biosynthesis (left) and salvage (right) pathways for glucosamine (GlcN). When GlcNAc is 
being catabolized or recycled, it is imported into the cell through either the NagE transporter or 
AmpG,D complex, respectively. If imported through AmpG,D, it must first be phosphorylated by 
NagK before entering the catabolic pathway catalyzed by NagA,B which feeds directly into 
glycolysis. The lower portion shows the anabolic pathway for activated UDP-GlcNAc through 
which either biosynthesized or salvaged GlcN-6-P is shuttled. Notice that E. coli lacks an agm1 
homolog (present in the listed species) that allows for direct salvage of GlcNAc. Once formed, 
UDP-GlcNAc can be acted upon by epimerases to generate a wide variety of activated N-
acetylhexosamines for use in various biosynthetic pathways including peptidoglycan and LPS.   
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N-linked protein glycosylation in bacteria  
 Bacterial glycobiology garnered new attention when N-linked protein glycosylation was 
discovered in bacteria. Specifically, the pathogen Campylobacter jejuni was shown to produce 
N-linked glycoproteins by research in 1999[7]. In a system that is like the N-linked glycosylation 
pathway in eukaryotic cells, lipid linked oligosaccharides are transferred onto acceptor proteins 
in the periplasm by an oligosaccharyltransferase (OST). The prokaryotic OST (PglB) is a single 
subunit that is most analogous to the Stt3 subunit in the eukaryotic OST complex. Instead of the 
dolichol linked glycans of the eukaryotic system, C. jejuni PglB takes advantage of the 
periplasmic UPP-linked oligosaccharides by transferring the glycan en bloc to an acceptor 
protein.  Like the eukaryotic OST complex, the C. jejuni PglB has a specific acceptor sequon that 
contains the asparagine to be glycosylated.  Specifically, it is the five amino acid sequence D/E-
X1-N-X2-S/T where X1 and X2 are any amino acids except proline. This is a more stringent 
requirement than that of the eukaryotic acceptor sequence which is less strict at only three 
amino acids N-Y-S/T [22, 23]. Numerous studies have shown that the sequence which is 
glycosylated most efficiently by C. jejuni PglB is DQNA[22]. This observation led to the 
development of the so-called “4xGlyc tag”, a series of four repeating DQNAT sequences 
separated by serine linkers[11]. This new tag, which could easily be added to the terminal 
sequence of a protein, facilitated easy engineering of novel glycoproteins in E. coli.  
 The recombinant pgl locus has been used in E. coli to transfer the C. jejuni 
heptasaccharide to a wide variety of target proteins from small monomeric proteins like single 
chain variable fragments (scFvs) to large secretory toxins like Cholera toxin's B subunit (CtxB) 
and even integral membrane proteins such as cytolysin A (ClyA)[10, 22, 24].  In addition to 
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being able to transfer glycans onto many different classes of protein, PglB has also been able to 
transfer a wide range of glycans onto those proteins. The list of glycans includes the native C. 
jejuni heptasaccharide, the O-antigens of several Gram-negative species such as F. tularensis, 
and eukaryotic glycans such as the trimannosyl core glycan and the tumor associated T 
antigen[9, 10, 24, 25].  Despite its apparent flexibility for different protein and LLO substrates, 
PglB is limited by its rigid acceptor sequence and by the requirement that the glycan to be 
transferred has an N-acetylhexosamine as its first residue. Work has been done to generate 
mutated PglBs that have an altered sequence specificity and no longer require an N-
acetylhexosamine as the base sugar [26]. These modified PglBs have been used to transfer 
novel glycans such as Salmonella enterica O-antigen onto acceptor proteins, and they have 
been used to glycosylate previously intractable targets that are glycosylated in mammalian 
systems but not in bacterial.  The ability to transfer any UPP linked glycan onto any target or 
carrier protein, or protein glycan coupling technology (PGCT), has provided a powerful tool for 
the biosynthesis of glycoconjugates including glycoconjugate vaccine[9, 10, 26-28]. Though this 
method of producing glycoconjugates is both attractive and elegant in that it is complete 
biosynthesis of protein glycoconjugates without any downstream processing, its 
implementation is not always straightforward. First, PGCT requires the successful identification 
and transfer of a glycan biosynthetic pathway into E. coli, which can be time consuming 
depending on how well understood the biosynthetic pathway is. Additionally, the glycan 
biosynthetic pathway must be relatively orthogonal to endogenous glycobiology. The 
heterologous pathway starts with a readily available metabolite(s) in E. coli and can reproduce 
the recombinant glycan authentically. In an even more undesirable scenario, it may be that a 
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clear biosynthetic pathway for the desired glycan doesn't exist, requiring the researcher to 
engineer a novel pathway.  Finally, though the path to purified glycoconjugates produced from 
PGCT is much clearer than for glycoconjugates produced by traditional semi-synthetic 
chemistry, a purification of glycoprotein from other cellular components is still required.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Bacterial N-linked protein glycosylation via the C. jejuni pgl pathway. This cartoon 
illustrates how the genes of the pgl locus use common metabolites such as UDP-GlcNAc to construct the 
unique heptasaccharide glycan. Notice the di-N-acetylbacillosamine (UDP-dNAcBac) as the first sugar 
being placed on UPP. If pglD is inactivated, dNAcBac is replaced by the more common GlcNAc as the first 
sugar residue [23]. The three components of the protein glycosylation reaction come together on the 
right-hand side of the cartoon. These three components (LLO, OST, and target protein) can be combined 
in vitro to carry out the protein glycosylation reaction. Not shown is PglG, as it plays no role in protein 
glycosylation[29].   
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Vaccine Immunology  
 Vaccines are one of the greatest advances in the history of medical science.  They have 
been used to effectively eradicate several diseases including smallpox and polio, and they have 
dramatically decreased the incidence of other diseases including rabies, mumps, and measles.  
The modern vaccine formulations for these previously listed diseases have changed little from 
their historical formulations.  Each of these vaccines is comprised of either an attenuated or 
killed sample of the pathogen responsible.  The body’s response to these vaccines is very similar 
to its response to the actual pathogen.  The killed or attenuated pathogens contain many 
pathogen-associated molecular patterns (PAMPs) including LLOs and CpG DNA that are 
recognized by elements of the innate immune system including Toll-like receptors.  Exposure to 
these PAMPs causes rapid production and release of immunostimulatory and inflammatory 
cytokines that recruit professional Antigen Presenting Cells (APCs) such as dendritic cells (DCs) 
to the site of exposure [30].  The recruited APCs then phagocytose the attenuated or killed 
pathogen and display digested peptide fragments from the pathogens on major 
histocompatibility complexes (MHCs).  These APCs then bring the antigen fragments displayed 
on MHCII back to lymph nodes where naïve T-cells and B-cells are exposed to antigen.   How 
these naïve cells respond to antigens presented on MHCs depends on the naïve cell type and 
the class of MHC presenting it [31]. 
 Naïve B-cells with B-cell receptors (BCRs) that are specific to the antigen internalize it.  
Classically, antigens that are endocytosed by professional APCs are processed in lysosomes and 
loaded onto MHC class II complexes.   Naïve CD4+ T-cells are also exposed to the processed 
antigen presented on MHCII, and if their T-cell receptors (TCRs) are specific to the antigen, they 
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too will proliferate and differentiate into effector T-cells.  When a B-cell that is displaying an 
antigen on MHCII encounters a cognate CD4+ T-cell, there is a co-stimulation of proliferation 
and differentiation in both the T-cell and B-cell that leads to clonal selection of both cells and 
subsequent differentiation into plasma cells and effector helper T-cell [31]. This interaction 
results in production of high titers of class switched antibodies and is generally directed toward 
and effective against extracellular pathogens such as Staphylococcus aureus, Streptococcus 
pyogenes, Neisseria meningitidis, and Yersinia pestis.      
 Whereas MHCII generally displays peptides from exogenous antigens that are 
endocytosed by professional APCs, MHC class I displays endogenous antigens that are degraded 
in the cytoplasm. Unlike MHCII, which is generally only present on professional APCs, MHCI is 
present on almost every nucleated cell.  Endogenously produced proteins are degraded within 
the cytosol and retroactively transported into the ER where the peptide fragments are loaded 
onto MHCI before being exported to the surface.  In this way, MHCI functions as a reporter for 
aberrant protein production within cells such as when the cell is infected with a virus.  If APCs 
become infected with a virus, they will also express viral proteins which are processed and 
displayed on MHCIs.  When these infected APCs encounter naïve CD8+ T-cells with TCRs that are 
specific to the viral antigens, the CD8+ T-cells proliferate and differentiate to become cytotoxic 
T-cells (TCs).  If these TCs encounter the same antigen presented by MHCI on other cells, the 
TCs induce apoptosis of the infected cell. Production of these TCs is generally known as the 
cellular immune response and is generally directed toward intracellular pathogens [31].    
  Though all cells have the potential to display endogenous antigens on MHCI, it has been 
observed that DCs can “cross present” exogenously translated proteins on MHCI [32, 33].  
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Through a poorly understood mechanism that involves retrograde vesicular transport and/or 
fusion of the vesicle with the endoplasmic reticulum, DCs have been shown to process 
exogenous protein antigens and display them on MHCI [34].  It is in this way that a non-viable 
viral particle or a component of an intracellular pathogen in a vaccine is able to elicit a relevant 
TC immune response that leads to death of infected cells [35].  
 Though the adaptive immune response to protein antigens is well understood, our 
conception of how the immune system responds to non-classical antigens such as LLOs or 
polysaccharides is still changing. The immune system can generate a glycan specific immune 
response through the previously described canonical method through one of two ways. First, if 
the glycan component of a glycoconjugate protein is recognized by a BCR, the entire protein 
can be endocytosed, processed, and displayed on MHCII, allowing for clonal expansion of the 
naïve B- cell and production of glycan specific antibodies[36, 37]. Second, if the glycan 
recognized by a naïve BCR is zwitterionic, once it has been endocytosed, the glycan can fit into 
the peptide binding cleft and be directly displayed on MHCII, allowing for clonal expansion of 
the B-cell and the glycan specific T-cell[38, 39]. There are, however, cases where class-switched 
glycan specific antibodies are produced when neither of the above two conditions are 
satisfied[15, 16]. How these glycans elicit such a strong humoral immune response is still poorly 
understood. 
  It is known that APCs can display LLOs to T-cells through presentation on CD1, allowing 
for progression of an immune response similar to that observed during classical peptide antigen 
display[37].  It is also possible for LLO or polysaccharide antigens to raise a humoral immune 
response through T-cell independent activation of naïve B-cells [40].  B-cells can be activated 
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and undergo proliferation, antibody class switching, and differentiation into plasma cells if the 
BCRs on naïve B-cells undergoes antigen mediated oligomerization in conjunction with strong 
immunostimulatory signals. This type of activation occurs when BCR binds to repeating subunits 
that are regularly spaced near each other. The repeating subunits of PS and LPS antigens makes 
them ideal antigens for this type of B-cell activation if they are co-administered with strong 
stimulators of the innate immune system [41]. 
 
Outer Membrane Vesicle Vaccines 
 Outer membrane vesicles (OMVs) are naturally produced liposomes that bleb off from 
Gram-negative bacteria.  Their membrane composition is very like that of bacterial outer 
membranes and they range in size from approximately 50-250nm in diameter.  They display 
integral outer membrane proteins, glycolipids, and polysaccharides on their outer surface.  The 
lumen of OMVs contains periplasmic components including soluble proteins and peptidoglycan 
[42, 43].  The biological functions of OMVs are manifold and include moderation of membrane 
stress through shedding, transportation of soluble toxins or virulence factors during 
pathogenesis, and modulation of the host immune response during colonization [17, 44-49]. 
The extraction and recovery of OMVs is relatively straightforward, requiring two rounds of 
centrifugation separated by sterile filtration[42, 43, 50].   
 It has previously been shown by the DeLisa Research Group and others that OMVs have 
a potent immunostimulatory effect due to the many PAMPs in their composition [44, 45, 51, 
52].  Additionally, OMVs contain many of the antigenic peptides and glycolipids that are often 
critical to developing an effective immune response to infection by Gram-negative bacteria.  It 
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is for these reasons that OMVs are attractive candidates for vaccines against Gram-negative 
bacteria.  Unfortunately, it is hard to obtain significant quantities of OMVs from pathogens as 
they are often difficult to culture at high density and the constitutive rate of OMV production 
can be quite low.  Additionally, naturally derived OMVs tend to contain a large amount of LPS 
which can cause sepsis [53].  To overcome these limitations of native OMVs in current methods, 
the outer membrane of a Gram-negative bacterial pathogen is often partially solubilized with 
detergents to form OMVs. These harvested OMVs have modified lipid compositions that do not 
contain LPS, making them much less reactogenic. This was the approach taken during the 
recent development of the multi-subunit vaccine against Neisseria meningitidis type B[54].  
Some of the downsides to this approach are that it is costly and that it can exclude some 
naturally occurring antigens from the OMVs such as O-antigens displayed on LPS. Additionally, 
it does not overcome the challenge of having to culture the pathogen of interest at high 
densities.  
 An alternative approach to generating OMVs for vaccines is through the use of 
recombinant OMV technology which allows us to express relevant antigens from pathogens in a 
non-pathogenic Gram-negative host such as E. coli.  By targeting glycolipids and integral 
membrane protein antigens to the outer membrane and by localizing soluble antigens to the 
periplasm, it is possible to create recombinant OMVs with heterologously expressed antigens 
from pathogens [13, 14, 43, 55].  In addition, it is possible to induce hypervesiculation in E. coli 
without affecting cell viability via genetic knockouts [14, 50].  It is also possible to make 
recombinant OMVs from strains of E. coli that have modified LPS structure so that the lipid A 
portion of the molecules are much less reactogenic[56]. Thus, it is possible for recombinant 
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OMVs produced in E. coli to overcome the challenges presented by using native OMVs from 
pathogens. Recombinant OMVs produced from hypervesiculating strains of E. coli have been 
used to successfully immunize animals with a variety of antigens including glycans [13, 14].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Engineering capability of recombinant OMV vaccines. OMVs have been engineered for 
vaccine development in several ways. Strains of E. coli have been made to hypervesiculate though 
genetic deletion of genes such as tolR,A, and nlpI (Kuehn, 2006). Recombinant protein antigens can be 
targeted to the surface of the OMVs through fusion with outer membrane proteins or to the lumen of 
OMVs through targeting to the periplasm (Rosenthal, 2014). Any glycoengineering that of extracellular 
polysaccharides affects glycans on the OMVs, allowing for delivery of carbohydrate antigens (Chen, 
2016). Additionally, OMVs can be produced from strains of E. coli with modified lipid A structure, 
decreasing their reactogenicity (Chen, 2016).  
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CHAPTER 2 
 INCORPORATING BIOORTHOGONAL SUGARS INTO E. COLI LLOS 
Introduction 
 Bioorthogonal chemistry is the study of reactions that do not interfere with normal 
biological processes and are thus "orthogonal" to them. It has become a useful tool for labeling 
specific metabolic products in living cells. An example of bioorthogonal chemistry in biology is 
the incorporation on non-canonical or chemically modified amino acids to create novel 
products form a synthetic biology approach and as an investigative tool in developmental 
biology[57-67]. The incorporation of novel amino acids into proteins structures is relatively 
straightforward as protein biosynthesis is a well-known and template-driven process[66]. In 
contrast, the use bioorthogonal chemistry in glycobiology can be more difficult in glycobiology 
as it is a much less mature field and the production of glycans is much more stochastic than the 
template driven processes of protein biosynthesis. Additionally, as carbohydrates are the 
primary source of energy for cellular metabolism, it is likely that any chemically modified sugars 
will be degraded by a cell as a matter of course. These challenges for bioorthogonal chemistry 
in glycobiology must be taken into consideration when developing methods for its use.  
 Carolyn Bertozzi and others have developed a method for chemically labeling glycans in 
living cells using bioorthogonal chemistry [58]. Their method takes advantage of the 
bioorthogonal reaction discovered in 1919 known as the Staudinger reaction[68]. The reaction 
occurs between a phosphine and an azide to produce an aza-ylide intermediate which normally 
would hydrolyze in water to form a primary amine and a phosphine oxide. However, if the aza-
ylide forms with a nearby electrophilic trap and appropriate leaving group, water can facilitate 
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the formation of an amide bind between the two molecules, resulting in a Staudinger ligation 
(Figure 2.1a)[58]. This reaction is bioorthogonal and biocompatible in that neither the azide or 
phosphine groups interact significantly with biomolecules and that this reaction occurs in water 
under physiological condidtions.  The Bertozzi group found that acetylated azide labeled sugars 
(azidosugars) are readily incorporated along with endogenous sugars using anabolic pathways, 
facilitating the labeling of a wide variety of cells types with phosphine-labeled fluorophores. 
This method facilitated the study of developmental biology and glycobiology in living organisms 
(Figure 2.1a)[62-64]. More recently, Danielle Dube has used similar methods to study bacterial 
glycobiology in Helicobacter pylori[69]. In this chapter, I will discuss the metabolic engineering 
of E. coli to allow for similar labeling E. coli glycans and demonstrate that labeling via flow 
cytometry (Figure 2.1b).  
 
Results 
I have previously discussed hexosamine glycobiology in E. coli (Figure 1.1). Specifically, 
while E. coli is capable of internalizing GlcNAc, it must first be broken down to GlcN-6-P before 
it can be used in anabolic pathways. This lack of a direct salvage pathway for GlcNAc precludes 
the use of azide-labeled GlcNAc (GlcNAZ) in E. coli. The required metabolic modifications to 
facilitate the use of GlcNAZ are outlined in Figure 2.1b. First, the catabolic pathway for GlcNAc 
was deleted via knockout of the nagA gene. Second, a pathway for the direct conversion of 
GlcNAc-6-P to UDP-GlcNAc was created by the addition of two genes from S. cerevisiae, agm1 
and uap1. The gene agm1 encodes a phosphoacetylglucosamine mutase which converts 
GlcNAc-6-P to GlcNAc-1-P, and uap1 is a UDP-N-acetylhexosamine pyrophosphorylase which 
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then converts GlcNAc-1-P to UDP-GlcNAc. The endogenous E. coli gene, glmU could 
theoretically also provide this activity, but as it is a two-subunit protein with two distinct 
catalytic activities and substrate binding affinities, we theorized adding an enzyme with 
specialized activity (uap1) would result in better incorporation of GlcNAZ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Staudinger ligation and engineered GlcNAZ salvage pathway. The left panel (a) shows the 
mechanism of the Stuadinger ligation and the two reactants used in this study, tetra-acetylated GlcNAZ 
and the fluorophore AlexaFluor 488-Phosphine (Saxon and Bertozzi, 2000). The right panel (b) shows the 
engineered salvage pathway for GlcNAc that the facilitates the use of GlcNAZ in E. coli. The black arrows 
and gene names are endogenous to E. coli while the red arrows and genes are from S. cerevisiae and are 
heterologously expressed. The red/black hatched arrow shows a reaction that is facilitated by both 
endogenous and heterologous genes.  
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 A strain of E. coli harboring a nagA deletion (BRL04) was graciously provided by Ben 
Lundgren along with pBRL178, a plasmid encoding the bicistronic expression of agm1 and 
uap1[70-72]. The BRL04 cells were transformed with pBRL178 and cultured to mid-log phase in 
a LB medium supplemented with variable amounts of IPTG inducer and either Ac4GlcNAc or 
Ac4GlcNAZ. The cells were then washed and labeled with AlexaFluor 488-Phosphine, and their 
fluorescence was quantified via flow cytometry (Figure 2.2). It is clear that induction of the 
salvage pathway had an effect on the azide incorporation into sugars displayed on the outer 
surface of the E. coli (Figure 2.2). It was later found that the cells which were apparently labeled 
in the absence of an azido-sugar where in fact just made permeable to the dye by induction of 
the salvage pathway. We showed this was case by also labeling permeable cells with propidium 
iodide. When the permeable cells were removed from the analysis, azide-specific labeling was 
only observed in cells with both active salvage pathways and Ac4GlcNAZ supplemented media 
(Figure 2.2c,d and Figure 2.3). We also showed that we were able to label approximately 30% 
of all cells using total cell count, not just the number of non-permeable cells (Figure 2.3b).  
 
Discussion  
We have shown that E. coli containing a nagA deletion and heterologously expressing a 
bicistronic GlcNAc salvage pathway (agm1 and uap1) from S. cerevisiae is able to take up and 
use GlcNAZ in glycans displayed on the outer surface of the bacterium. We saw that the labeling 
of azido-sugar displaying E. coli was dependent on the strength of inducer concentration 
(Figure 2.2) and that a significant fraction of the population was observed to be labeled by flow 
cytometry (Figure 2.3).  
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Figure 2.2: Azide-specific labeling via induction of GlcNAZ salvage pathway. BRL04 cells were 
transformed with pBRL178 and cultured to mid-log phase in a LB medium supplemented with variable 
amounts of IPTG inducer and either 0.1mM Ac4GlcNAc or Ac4GlcNAZ. The cells were labeled with 
AlexaFluor 488-Phosphine, and their fluorescence was quantified via flow cytometry (FL1, arbitrary 
units). The permeability of cells was assessed by also incubating them with propidium iodide. Cells 
assessed as permeable to both dyes were removed from the analysis in the lower panels (c,d). 
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 Immediate future work on this project would include optimizing induction conditions for 
the expression of the GlcNAc salvage pathway. As we observed, induction of this pathway is 
required for the azido-sugar to be displayed on the surface of E. coli, but it also causes the cell 
to become permeable to two different fluorophores (Figure 2.2). After removing the permeable 
cells from the data analysis, approximately 30% of the population was labeled. While this 
labeling percentage is significant, pushing the fraction of azido-sugar displaying cells up to 100% 
via optimization of induction conditions (i.e. IPTG concentration, culture temperature, and 
culture medium) is desirable if this method is to be further developed.  
 Danielle Dube and colleagues have proposed to use azido-sugars in several different 
drug therapies, including an immunotherapy and an antimicrobial therapy[73, 74].  These 
applications are viable because of the bioorthogonal and biocompatible nature of the chemistry 
Figure 2.3: Population analysis of azide-labeled E. coli. BRL04 cells were transformed with pBRL178 and 
cultured to mid-log phase in a LB medium supplemented with either no inducer or 0.1mM IPTG and 
either 1.0mM Ac4GlcNAc or Ac4GlcNAZ. The cells were labeled with AlexaFluor 488-Phosphine, assessed 
for permeability with propidium iodided, and had their fluorescence quantified via flow cytometry. An 
FL1 signal of 500 to 10,000 was established as "labeled" and the fraction of each population in that 
range was evaluated. Cells assessed as permeable to both dyes were removed from the analysis. 
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used to conjugate drugs to azido-sugar displaying cells. Large-scale production of the azido-
sugars necessary for these treatments is an obstacle to overcome in the development of these 
drugs. Alternatively, we propose the use the use azido-sugars in the formulation of new vaccine 
candidates. As discussed in several other chapters of this work, Outer Membrane Vesicles 
(OMVs) are capable of carrying and displaying polysaccharides from the outer membranes of 
the bacteria from which they originate. Thus, we expect OMVs produced from recombinant E. 
coli that have incorporated GlcNAZ into their endogenous glcyans, specifically the Lipid-A core 
glycan, will display azido-sugars on their surface which can be used as convenient “handles” for 
chemical functionalization and conjugation, leading to the formation of a new host of vaccine 
candidates.  
    
Materials and Methods  
Bacterial strains and plasmids. The strains and plasmids used in this chapter are described 
below (Table 1.1) and were generously provided by Benjamin Lundgren. Briefly strains are 
based on the well-known strain E. coli K-12 MG1655. The strain BRL04 was constructed through 
the use of a λ(DE3) lysogen, Tn5 transposon, and P1 transduction[70]. The plasmid pBRL178 has 
the CDRs for agm1 and uap1 from S. cerevisiae expressed bicistronically under control of a T7 
promoter[71].  
Azido-sugar labeling and flow cytometry. Briefly, BRL04 cells were transformed with pBRL178 
using electroporation. Transformed cells were selected on medium supplemented with the 
appropriate antibiotic. Bacterial cells were labeled using a previously described method 
optimized for H. pylori[69]. An overnight culture of a single colony was selected and grown 
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overnight in Luria Bertani (LB) medium. Saturated overnights were subcultured 1:50 in LB 
supplemented with appropriate antibiotics and IPTG as well as a range of Ac4GlcNAc or 
Ac4GlcNAZ (generously provided by Danielle Dube) concentrations. The cultures were grown to 
mid-log phase (OD600 ≈ 0.6) at which point cells were pelleted via centrifugation at 6,000xg for 
10 minutes for, washed once with PBS, and resuspended to OD600 ≈ 3.0 in PBS with 100mM 
AlexaFluor 488-Phosphine (generously provided by Danielle Dube). Cells were incubated at 
room temperature for 4 hours before being pelleted and washed three times with PBS to 
remove unconjugated AlexaFluor 488-Phosphine. Cells were resuspended to a final OD600 ≈ 0.1 
before being stained with propidium iodided (Sigma) and assayed for fluorescence via flow 
cytometry on a FACSCalibur (BD Biosciences).   
 
 
Table 1.1: Bacterial strains and plasmids used in this chapter. 
Strain   Genotype   Source 
-BRL04   λ(DE3)nanT::Tn5(kan)-I-SceI nanA::tet ΔnagA [70] 
       
Plasmid   Description; Resistance marker   
-pBRL178   IPTG induced T7 biscistronic expression of S. cerevisiae 
agm1 and uap1; Amp 
[72] 
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CHAPTER 3 
PROTEIN GLYCOCONJUGATE OMV VACCINES 
Introduction 
 Bacterial glycans are key components in how bacteria interact with their environments. 
Polysaccharides present in, on, and around bacterial outer membranes help the cells with 
colonization of new environments, protection from biological threats, and modulation of host 
immune response. As complex carbohydrate molecules are integral to the interface between a 
bacterial cell and its environment, they are often key virulence factors during pathogenesis. 
Examples of these virulence factors include extracellular polysaccharides which facilitate biofilm 
formation. Pathogens like enteroaggretive E. coli (EAEC) use biofilms to colonize and survive in 
normally hostile, abioitc environments such as urinary tracts[75]. Capsular polysaccharides are 
an example of membrane associated polysaccharides that are often associated with 
pathogenesis. Attachment of the capsular polysaccharide of the Gram- positive pathogen 
Streptococcus pneumoniae to its cell wall is crucial for its pathogenesis of invasive disease[76]. 
Another example of a capsular polysaccharide virulence factor is the polysialic acid produced by 
the Gram-negative pathogen Nesseria meningitidis type B. The polysialic acid produce in the 
capsule of N. meningitidis B mimics glycans present on host cells, allowing the pathogen to 
evade the immune response[77].  Though not a polysaccharide, per se, the glycans present on 
N-linked glycoproteins play an apparent role in the colonization of C. jejuni as disruption of the 
pgl locus results is decreased infectivity of the pathogen[78]. The roles of polysaccharides and 
glycans as mediators of pathogenesis are clear, making them attractive targets for vaccine 
candidates.  
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 In order for a glycan targeted vaccine to be successful, it must be able to generate a 
robust and long lasting immune response by inducing the formation of glycan specific, class-
switched antibodies. A fundamental problem with this approach is that subunit vaccines 
consisting of bacterial glycans and polysaccharides have generally been unable to elicit this type 
of immune response. Glycan antigens are generally T-cell independent antigens which means B-
cells generating glycans specific antibodies are unlikely to undergo class switching from IgMs to 
other more potent isotypes and are unlikely to generate any glycan specific memory B-cell or T-
cells[39]. This lack of development of B-cells with glycan specific antibodies is due to their 
inability to recruit cognate T-cells as carbohydrate antigens are generally not loaded onto 
MHCIIs. A modern method for overcoming this limitation involves chemically conjugating the 
carbohydrate antigen onto a protein carrier that is known have robust TCR binding epitopes. By 
endocytosing these glycoprotein conjugates, B-cells with glycan specific antibodies are able to 
process and display TCR epitopes on MHCII, allowing for clonal expansion and differentiation 
into plasma cells and memory B-cells [4, 5]. This approach led to the creation of successfull 
vaccines against Haemophilus influenzae, Streptococcus pneumoniae, Nesseria meningitidis, 
and others[3, 5].  
 Though this method of creating protein glycoconjugates via chemical semi-synthesis led 
to the production of several vaccines, there are several drawbacks associated with it. First, this 
approach requires the isolation of polysaccharide directly from pathogens which must be 
cultured to sufficient density. Pathogens can be difficult to culture, often requiring esoteric 
nutrients in their growth media to reach sufficient density. Adding in safety concerns and the 
associated costs makes the large-scale culturing of pathogens an unappealing prospect for 
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making a product that does not have an associated medical urgency. Similarly, the chemistry for 
protein glycan coupling can be untargeted and inexact, requiring costly purification of the 
glycoprotein. These concerns can be addressed by protein glycan coupling technology (PGCT), 
which enzymatically creates glycoproteins using wholly recombinant components [24]. Using 
PGCT, novel glycoprotein vaccine candidates have been made against several bacterial 
pathogens[9, 10, 26, 28]. Potential vaccines against one target pathogen in particular, 
Francisella tularensis, have benefited from this technology.  
 F. tularensis is an intracellular Gram-negative pathogen that is classified as a biodefense 
category A pathogen by the NIAID due to its high infectivity and ease of dissemination. No 
licensed vaccine against it currently exists though there is a live vaccine strain (LVS) that can be 
administered to at-risk populations[79].  Like most Gram-negative pathogens, F. tularensis has 
an outer membrane comprised primarily of lipopolysaccharide (LPS).  The major antigenic 
subunit of this LPS is a repeating oligosaccharide subunit known as an O-antigen.  In previous 
studies examining the immune response against F. tularensis and the effectiveness of potential 
vaccines, it has been shown that an immune response against the O-antigen is helpful for 
clearing infection[80-82]. In an attempt to create a more effective vaccine, PGCT in E. coli was 
used to create a protein glycoconjugate vaccine against F. tularensis using a recombinant O-
antigen biosynthetic pathway, C. jejuni PglB as the OST, and a detoxified Pseudomonas 
aeruginosa exotoxin A as the carrier protein[83]. This purified glycoconjugate vaccine was able 
to generate a robust humoral immune response against the O-antigen and confer an extended 
time to death on mice infected with F. tularensis holoartica, one of the less virulent strains of F. 
tularensis. More recently, the DeLisa Research Group has produced a glycOMV vaccine that was 
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able to confer protection against lethal challenge with the highly virulent F. tularensis ShuS4 
strain in mice[16].  These works suggest that a possible direction for future vaccines.  
 In this chapter, I will discuss combining the two previous approaches using PGCT and 
OMVs to create a single vaccine formulation. My approach uses the versatility and specificity of 
PGCT and combines it with the immunostimulatory power of OMVs. It can be generalized to 
any Gram-negative pathogen possessing an O-antigen, but as a first target, I have chosen F. 
tularensis. By expressing the recombinant O-antigen pathway from F. tularensis in an 
appropriate glycoengineered hypervesiculating strain of E. coli along with an appropriate 
periplasmically expressed carrier, I have created OMVs containing lumenal glycoprotein 
antigens. The carrier protein chosen for this study were scFv13R4-4xGT, a single chain variable 
fragment whose soluble expression in the periplasm of E. coli has been optimized and 
conjugated to a “4xglyc-tag”, MBP-4xGT, E. coli maltose-binding protein conjugated to a 
“4xglyc-tag” which has been shown to have strong TCR binding epitopes[84], and EPA, 
Pseudomonas aeruginosa exotoxin A which has been genetically modified to no longer be toxic 
and has two bacterial glycosylation sites engineered into sequence[10]. Conjugating the F. 
tularensis O-antigen to these carrier proteins and loading them into an OMV is expected to 
elicit a more robust and long term immune response to the O-antigen and thus provide better 
protection against F. tularensis challenge than either the glycoconjugate or glcyOMV alone. 
Additionally, we have performed in vitro protein glycosylation (IVPG) on OMVs displaying ClyA-
GT, E. coli hemolysin A conjugated to a “4xglyc-tag”.  
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Results 
Selection of an appropriate glycoengineered, hypervesiculating strain for in vivo PGCT. To 
produce OMVs containing a higher yield of glycoproteins, we tested several hypervesiculating 
strains for their ability to produce glycoconjugates both in the periplasm and in OMVs. The well-
studied hypervesiculating strain JC8031 that contains knockouts of tolR and tolA was used as a 
starting point for the production of glycoproteins [85]. However, it is known that by knocking 
out the endogenous waaL gene, the transfer of glycans from UPP to Lipid A is abolished, leading 
to an increase in the LLO substrate available to PglB. This increase in the substrate pool is 
thought to increase the glycosylation efficiency for the PGCT. The DeLisa Research Group 
previously took advantage of this by creating the strain JC8032, which is JC8031ΔwaaL[24]. 
Alternatively, the strain CLM24 has been shown by our lab and others to be able to produce 
efficiently glycosylated proteins [9, 10, 24, 86].  In order to increase the yield of OMVs from 
CLM24, we took advantage of the previous observation that knocking out nlpI from E. coli yields 
a hypervesiculating strain with no significant detriment to cell viability or membrane integrity  
[50].  By comparing production of carrier proteins to glycosylated carrier proteins in the 
periplasm of these three strains, we can see that CLM24ΔnlpI produces the most 
glycoconjugate (Figure 1.1). The characteristic O-antigen MW laddering that is a result of 
variable polymer length is clear in all cases where active PglB was expressed. Most the 
glycoprotein appears at or slightly above the MW for aglycosylated MBP-4xGT (Figure 1.1 
bottom). This intense band around the MW for MBP-4xGT suggests that the glycosylated form 
predominantly contains lower order oligomers of O-antigen subunits. 
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  By also comparing the amount of glycoproteins in OMVs produced from these strains, 
we again see that CLM24ΔnlpI produces OMVs containing the most glycoprotein (Figure 3.2) 
relative to total protein content. While the trend observed here is using maltose-binding 
protein as the carrier, a similar trend was observed for both scFv13R4 and Pseudomonas 
aeruginosa exotoxin A (EPA) (Figure 3.3) (Data not shown for production of scFv13R4 and EPA 
in JC8031 or JC8032). In creating CLM24ΔnlpI, we have constructed a hypervesiculating strain of 
E. coli well suited for performing in vivo glycosylation  
 
 
 
 
 
 
 
 
 
 
 
  
 The glycosylation pattern of scFv13R4-4xGt and EPA shows that they are present in 
OMVs and that they are protected from degradation with proteinase K (Figure 3.3).  This 
observation suggests that EPA is located within the OMVs and that the proteinase cannot 
Figure 3.1: Comparison of periplasmic glycoprotein yield in three hypervesiculators. The protein MBP-
4xGT was targeted for periplasmic expression in strains expressing the biosynthetic pathway for F. 
tularensis O-antigen. The glycoprotein yield was compared using Western blotting. Top is the anti-His 
blot for MBP detection and bottom is the anti-Fb11 blot which detects the F. tularensis O-antigen. The (-
/+) represents the inactive (-) vs. active (+) C. jejuni PglB. All samples were normalized by total protein 
content as determined by BCA. Note: This Western blot was performed by Dr. Kristina Overkamp.  
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access it for degradation.  The evidence for lumenal glycoproteins is strengthened by the 
observation that lysing the OMVs prior to proteinase treatment by boiling them removes the 
signal from EPA and that glycoforms are only present in OMVs produced from cells expressing 
active PglB (Figures 3.2 and 3.3).  The prominent lower molecular weight bands apparent in the 
EPA OMVs are likely EPA degradation products (Figure 3.3 bottom right).  As the two 
engineered glycosylation sites on EPA are internal, it is probable that EPA is getting cleaved at a 
site between them, resulting in two lower molecular weight bands whose mass sum to that of 
full-length EPA. Additionally, we have often observed a strong 50kDa band in the anti-His blot 
for EPA, suggesting that this larger fragment is the C-terminal fragment containing the His tag. 
Indeed, EPA is known to have a protease specific site that is key to its biological function 
between the N- and C-terminal domains[87]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Comparison of glycoproteins in OMVs from three hypervesiculators. The protein MBP-4xGT 
was targeted for periplasmic expression and subsequent glycosylation and loading in the lumen of 
OMVs. Top is the anti-His blot for MBP detection and bottom is the anti-Fb11 blot which detects the F. 
tularensis O-antigen. The OMVs were either left untreated (-), were treated with proteinase K (+), or 
pre-boiled before being treated with proteinase K (*). The proteinase K digestion shows that 
glycoprotein antigens are indeed loaded in vesicles and partially protected from degradation with 
proteinase K. Samples were normalized by total protein content as measured by BCA. Note: These 
Western blots were performed by Dr. Kristina Overkamp. 
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Determining optimal conditions for in vitro protein glycosylation (IVPG) using recombinant F. 
tularensis O-antigen LLOs. As a proof of concept to demonstrate LLOs containing 
immunologically relevant recombinant oligosaccharides can be used as a substrate for in vitro 
glycosylation, we have performed IVPG on both MBP-4xGT and EPA using purified carrier 
proteins, purified LLO extracts from E. coli CLM24 transformed with the plasmid encoding the 
biosynthetic pathway for F. tularensis O-antigen to produce E. coli/F.tularensis hybrid LLOs, and 
purified C. jejuni PglB. After several attempts, we found that running the IVPG reaction at 30˚C 
for 6 hours resulted in the most efficient protein glycosylation as determined by densitometry 
of Western blots comparing intensities of glycosylated vs. a-glycosylated bands (data not 
Figure 3.3: Use of Clm24ΔnlpI to produce glycoprotein loaded OMVs. The carrier proteins used here are 
scFv13R4-4xGT and EPA. They have been targeted to the periplasm for glycosylation with F. tularensis O-
antigen and subsequent loading into OMVs. Top is the anti-His blot for carrier protein detection and 
bottom is the anti-Fb11 blot which detects the F. tularensis O-antigen. The cells were expressing C. jejuni 
PglB in either wild-type PglB (pglB) or catalytically inactive double mutant PglBD54NE316E (pglB**). The 
OMVs were either left untreated (-), were treated with proteinase K (+), or pre-boiled before being 
treated with proteinase K (*). The proteinase K digestion patterns show that glycoprotein antigens are 
indeed loaded in vesicles and protected from degradation with proteinase K. Samples were normalized 
by total protein content as measured by BCA. 
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shown). During these optimization experiments, it was determined that the detergent DDM in 
the IVPG reaction buffer caused oligomerization of EPA, but adding the rest of the IVPG 
reaction components resolved the oligomer back into a monomer on Western blots (Figure 3.4 
top). We have shown that is possible to glycosylate EPA and MBP-4xGT using IVPG (Figure 3.4) 
and that while overall glycosylation efficiency may be lower, the transfer of higher order O-
antigen polymers is much greater when using IVPG as compared to the glycoproteins produced 
in vivo (Figure 3.4 bottom).   
 
 
 
 
 
 
 
 
 
 
In vitro protein glycosylation can be used to directly glycosylate outer membrane proteins 
displayed on OMVs. To develop a novel method for creating glycoprotein containing OMVs, we 
have performed IVPG directly on proteins displayed by OMVs. Here, we have the previously 
generated E. coli hemolysin construct with a 4xGlycTag and expressed in the hypervesiculating 
strain JC8031[85]. We then took those OMVs and used them as substrates for IVPG. Not 
Figure 3.4: In vitro glycosylation of MBP-4xGT and EPA with O-antigen. Figures above show anti-His 
(top) and anti-FB11 (bottom) Western blots of in vitro protein glycosylation reactions performed at 30⁰C 
for 6 hours.  Samples were normalized by purified protein content (10µg) as measured by BCA. The (+) 
indicates the presence of the associated reaction component. The right two lanes are negative controls 
without an acceptor protein.  
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knowing whether these OMVs could function as suitable substrates for the in vitro reaction, we 
performed IVPG using C. jejuni PglB and its native heptasaccharide substrate as well as the F. 
tularensis O-antigen LLOs. Upon subsequent Western blotting, we saw the apparent formation 
of glycosylated ClyA-4xGlycTag when both LLOs were used as substrates (Data not shown). 
After establishing that ClyA-4xGlycTag can be glycosylated in OMVs, we then showed through 
density gradient ultracentrifugation that the OMVs remained intact after undergoing in vitro 
glycosylation (Figure 3.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Density gradient fractionation of OMVs glycosylated in vitro. The E. coli hemolysin A (clyA) 
was modified to have a 4x-GlycTag at its C-terminus. OMVs ClyA-4xGlycTag were used as substrates for 
IVPG with purified C. jejuni PglB and recombinant heptasaccharide LLOs. Those OMVs were then 
subjected to density gradient ultracentrifugation and subsequent Western blotting for detection of the 
protein with an anti-His antibody and detection of glycoprotein with anti-C. jejuni glycan antibody. Lanes 
are numbered by fractions with increasing density (1 being lowest and 12 being highest). The lane 
labeled "pre" shows the whole OMV prep before it is subjected to density gradient ultracentrifugation.  
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Discussion  
 We have created a glycoengineered, hypervesiculating strain of E. coli as a platform for 
the production of glycoconjugate OMV vaccines (CLM24ΔnlpI). We have shown production of 
three different N-linked glycoproteins with the F. tularensis O-antigen in CLM24ΔnlpI and that 
all three glycoproteins are protected from proteinase K degradation, which is consistent with 
the expected lumenal packaging of these glycoprotein antigens. As most of the glycoproteins 
we observed in OMVs had low order oligomerization of the O-antigen subunits, it may be that 
cargo protein size is a limiting factor in packaging lumenal OMV proteins. It may be that 
glycoconjugates with higher order oligomers are essential to eliciting a protective immune 
response. If this were to be the case, or second method for producing glycoconjugate OMV 
vaccines would be able to overcome it.  
 The toxin hemolysin A (ClyA) has been used as a carrier protein to shuttle recombinant 
protein antigens to the surface of recombinant OMVs[13, 14, 24, 88]. It has also been modified 
with a 4xGlycTag and used as a substrate for in vivo protein glycosylation by C. jejuni pgl 
pathway. Using in vitro protein glycosylation, we have shown direct glycosylation of ClyA-
4xGlycTag with both the C. jejuni heptasaccharide and the F. tularensis O-antigen. As expected 
from our previous in vitro glycosylation reactions with the F. tularensis O-antigen, the favored 
glycoprotein product consisted of longer length repeating O-antigen subunits. Additionally, we 
showed that the OMVs remained as intact liposomes after undergoing in vitro glycosylation by 
subjecting them density gradient ultracentrifugation and subsequent Western blotting. We 
clearly observed the co-localization of glycosylated ClyA in the same density regions where 
OMVs settle during ultracentrifugation. Using this direct in vitro glycosylation reaction on OMVs 
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may make it possible to create glycoprotein OMV vaccines that are intractable for in vivo 
glycosylation reactions.  
 The next step in this research is to evaluate the effectiveness of these glycoconjugate 
OMVs in an animal model. Performing a series of immunizations and challenges similar to those 
done by Chen, et al against F. tularensis would allow us to directly compare the effectiveness of 
this vaccine against glycOMVs. Future studies should include the lpxM deletion in ClM24ΔnlpI 
as this would allow for the creation of less reactogenic OMVs[16, 89]. It may also be that there 
are PglB homologs that are more efficient at transferring the F. tularensis O-antigen that should 
be used instead of the C. jejuni OST[90, 91].  We would directly compare the mouse immune 
response to O-antigen glycosylated lumenal EPA and glycosylated outer membrane displayed 
ClyA to each other as well as the purified glycoproteins by themselves. Unlike the F. tularensis 
glycolipid alone, we would expect there to be some immune response to the glycoprotein 
antigens alone. This comparison would allow to evaluate the immunostimulatory effects of 
OMVs on the glycan specific immune response to protein glycoconjugates. If these formulations 
of glycoprotein containing OMVs are not protective, we propose the use F. tularensis protein 
carriers that are known to have strong TCR binding epitopes[92]. 
 As previously discussed, the mechanism by which glycOMVs generate such a strong and 
protective antibody response remains elusive. A direct comparison of glycOMVs with more 
traditional glycoconjugate proteins loaded into OMVs may provide some insight into the 
immune response to glycolipids presented on OMVs. The use of multiple glycoprotein antigens 
(MBP, EPA, and ClyA) presented to the immune system in different contexts (lumenal vs. 
displayed) may also shed some light on the adaptive immune response to OMVs. Indeed it may 
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be that specific formats of glycoprotein containing OMVs can be tailored to specific pathogens 
of interest. If the immunization and challenge studies are carried out over longer time periods, 
we may find that glycoprotein containing OMVs provide a stronger, more protective immune 
response over longer time scales. In addition, if the immune response to glycoproteins with 
bacterial oligosaccharides is robust it may be that we could use engineered human-like glycans 
to create immunotherapies[15, 25].   
 
Materials and Methods 
Bacterial strains and plasmids. The strains and plasmids used in this chapter are described 
below (Table3.1). Briefly strains are based on the well-known hypervesiculating strain JC8031 
whose phenotype is attributed a knockout of tolRA, and CLM24, strain which lacks the waaL 
ligase[9]. Plasmid features are outlined below.  
Creation of hypervesiculating knockout strain via P1 transduction. Briefly, donor phages were 
created by incubating P1 phage with the member of the Keio collection that contains the nlpI 
gene knockout replaced by kanamycin [93]. After complete lysis of the donor culture, phage 
sample was clarified via centrifugation and stored at 4˚C until used. These phages were 
incubated with the CLM24 and incubated for 30 minutes at 37˚C. Lysis of the recipient phage 
was halted via the addition of 1mM sodium citrate before the cells were plated on kanamycin 
and sodium citrate. Several colonies were restreaked on kanamycin and sodium citrate. 
Knockout was verified by observation of hypervesiculation.   
Cell growth and subcellular fractionation of glycoproteins. Briefly, plasmids containing the 
necessary genes for N-linked protein glycosylation (Table 2.1) were transformed into different 
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strains using electroporation. In total, three plasmids are generally required for protein 
glycosylation: a periplasmically expressed target protein, a biosynthetic pathway for LLO, and 
an OST. Transformed cells were selected on medium supplemented with the appropriate 
antibiotic. An overnight culture of a single colony was selected and grown overnight in Luria 
Bertani (LB) medium. Saturated overnights were subcultured 1:50 in LB supplemented with 
appropriate antibiotics. The cultures were grown to mid-log phase (OD600 ≈ 0.6) at which point, 
target protein and PglB were was induced with an appropriate combination of L-arabinose 
(0.2%) and IPTG (0.1 mM). Induction was allowed to proceed for 16-20 hours at 37˚C. Cells were 
pelleted via centrifugation at 6,000xg for 10 minutes for subsequent subcellular fractionation. 
Whole cell fractions were simply removed and stored at -20˚C until they were used. Periplasmic 
fractions were obtained via previously described methods[94]. Briefly, pelleted cells were 
incubated on ice for 30 minutes in a buffer with high osmolarity (2M sucrose) and 0.15mg/mL 
lysozyme. Cells were then spheroplasted by osmotic shock via rapid dilution of the high 
osmolarity buffer. Spheroplasts were pelleted via centrifugation at 6,000xg for 10 minutes, and 
the periplasmic fraction was decanted from the supernatant. The OMV fractions were prepared 
as previously described[88]. Cell-free culture supernatants were collected post induction and 
filtered through a 0.2 µm filter. Vesicles were isolated by ultracentrifugation (Beckman-Coulter; 
TiSW28 rotor; 141,000xg; 3 h; 4˚C) and resuspended in PBS. OMVs were quantified by the 
bicinchoninic-acid total protein assay (BCA Protein Assay; Pierce) using BSA as the protein 
standard. 
Purification of target proteins for glycosylation. The purified MBP and EPA to be used as target 
protein for in vitro glycosylation were purified from the periplasm via previously established 
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methods[94]. The periplasmic extract of cells was loaded onto charged Ni-NTA resin in a gravity column 
in 10mM imidazole. The resin was then washed with 30mM imidazole before the target proteins were 
eluted with 200mM imidazole. Proteins were then concentrated to >1mg/mL via diafiltration 5kDa 
MWCO centrifugal filtration units (Millipore) into PBS (pH=7.0).   
Purification of PglB and LLOs. Purification of PglB and LLOs was carried out as previously 
described with a few modifications[91]. Briefly, CLM24 cells were transformed with pLAFR-
F.tularensis, pACYC-pgl::pglB, or psN28-pglB[12].  Cells were subcultured to mid-log phase and 
induced with 0.2% L-arabinose where appropriate.  After an 18 hour induction, cells were 
pelleted by centrifugation at 10,000 x g for 15 min. Pellets were resuspended in 50mM TrisHCl 
and 25mM NaCl (pH=7.0) at a concentration of 10mL per gram of pellet. Cells were lysed by 
freeze thaw, treated with 0.1μg/mL DNase, and homogenized using a microfluidizer. Lysate was 
clarified by centrifugation at 15,000 x g for 20 min.  Membrane extract was pelleted from 
supernatant by ultracentrifugation at 141,000 x g for 1 hour. Extracts were re-suspended using 
a manual homogenizer in 50mM TrisHCl, 25mM NaCl, and 0.1% N-dodecyl β-D-maltoside 
DDM(pH=7.0) to a final volume of 1 mL per gram of initial cell pellet. All buffers from this point 
on were modifications of this base recipe. Extracts were clarified by centrifugation at 16,000 x g 
for 1 hour, and supernatant was stored at 4⁰C.  For PglB purification, the solubilized 
membranes were supplemented with 10 mM imidazole and incubated with Ni-NTA resin for 1 
hours at room temperature. The PglB loaded resin was then applied to a gravity flow column 
and washed with 60 mM imidazole before PglB was eluted with 200 mM imidazole. The purified 
protein was then injected onto a Superdex 200 gel filtration column using AKTA-FPLC (GE 
Healthcare, Waukesha, WI) and fraction containing PglB were collected and assayed for activity. 
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 Plasmids carrying glycan biosynthesis pathways were freshly transformed into CLM24 
cells which were subsequently cultured LB. The culture was allowed to grow at 37˚C until OD600 
≈ 0.8 where the temperature was shifted to 30˚C and the culture was allowed to express O-
antigen biosynthesis pathway for 16 hours. The next day, cells were harvested and completely 
dried in a lyophilizer. The dried cell pellet was incubated with 10:20:3 v/v/v 
chloroform/methanol/water for 30 min. The organic layer was kept and the solvent was 
removed, yielding a dried extracted LLOs, which was then resuspended in glycosylation buffer. 
In vitro glycosylation reactions. The in vitro glycosylation reaction was carried out as previously 
described [12]. Briefly, target proteins EPA at 20μg/mL, MBP at 10µg/mL, and ClyA OMVs at 
10µg/mL were added to purified PglB or PglB** at 30µg/mL and F. tularensis or C. jejuni LLOs at 
100µg/mL in 10mM HEPES, 11mM McCl2, and 0.1%N-dodecyl β-D-maltoside (DDM) (pH=7.4). 
Reactions were allowed to run for 6 hours at 30⁰C.  
Density gradient ultracentrifugation. To ensure that the glycans detected on OMVs after in 
vitro glycosylation are OMV associated and that those OMVs are intact liposomes, glycosylation 
OMV samples were further purified by density gradient ultracentrifugation as previously 
described [88]. Briefly, OMVs were suspended in HEPES buffer (pH=6.8) instead of PBS and 
diluted into Optiprep solution to a final concentration of 1.0mg/mL in 1.5mL of 45% Optiprep 
solution in HEPES.  Discrete layers of Optiprep/HEPES were added to a 12mL ultracentrifuge 
tube by carefully pipetting more dense layers below less dense layers.  Each layer was added in 
330μL fractions with the following % composed of Optiprep: 10%, 15%, 20%, 25%, 30%, 35%, 
1.5mL OMV fraction containing 45% Optiprep, 9.0mL of 60% Optiprep to fill the tube.  The 
gradients were spun at 180,000xg for 3 hours after which thirteen 0.5mL fractions were taken 
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from the top of the centrifuge tube.  The samples were subjected to SDS-PAGE and analyzed by 
Western blot for the presence of glycosylated ClyA.  
 
Proteinase K degradation assay. To show that lumenal glycoproteins are in fact within the 
OMVs, recovered OMVs were diluted into PBS to a concentration 100μg/mL and incubated at 
37⁰C for 1 hour either with or without 1mg/mL proteinase K, or were boiled in 1% w/v SDS prior 
to treatment with 25μg/mL proteinase K to disrupt the OMVs. The digestion reaction was 
halted via the addition of 1mM phenylmethylsulfonyl fluoride (PMSF), and all samples were boiled 
prior analysis via Western blotting.  
Western blot analysis. Whole cell, periplasmic, and OMV samples were prepared for SDS-PAGE 
analysis by boiling for 15 min and cooling to room temperature in the presence of loading 
buffer containing β-mercaptoethanol. Samples were run on 10% cross-linked polyacrylamide 
gels (BioRad, MiniPROTEAN® TGX) and transferred to a PVDF membrane via semidry transfer. 
After blocking with a 5% milk in Tris-buffered saline (TBS), membranes were probed with HRP-
conjugated anti-His (Abcam) for the detection of carrier proteins (MBP, ClyA, scFv13R4, EPA). 
When analyzing samples for the presence of F. tularensis O-antigen, membranes were first 
probed with mouse monoclonal Fb11 (Abcam) and visualized with anti-mouse HRP-conjugated 
secondary (Promega). When analyzing samples for the presence of the C. jejuni 
heptasaccharide, membranes were first probed with the rabbit polyclonal serum HR6P (Aebi 
lab) before being probed with anti-rabbit secondary (Promega). Signal was visualized using HRP 
substrate Clarity ECL (BioRad) and imaged with a ChemiDoc XRS+ Imaging System (BioRad). 
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Table 3.1: Bacterial strains and plasmids used in this chapter. 
Strain   Genotype   Source 
-JC8031   supE hsdS met gal lacY tonA ΔtolRA [85] 
-JC8032   JC8031ΔwaaL  [24] 
-CLM24   W3110ΔwaaL  [9] 
-CLM24ΔnlpI  CLM24ΔnlpI; Kan  This study 
       
Plasmid   Description; Resistance marker   
-pGAB2   F. tularensis O-PS antigen gene cluster in pLAFR1; Tc [83] 
-pTrc99a   IPTG inducible expression vector; Amp Lab stock 
-pGVXN-150-EPA  arabinose inducible, periplasmic EPA expression vector; 
Amp 
[10] 
-pTrc99a-ssDsbA-MBP-
4xGlycTag 
IPTG inducible expression vector for periplasmic expression 
of MBP-4xGlycTag; Amp 
[24] 
-pTrc99a-ssDsbA-scFv13R4-
4xGlycTag 
-pBad18a-ClyA-4xGlycTag 
IPTG inducible expression vector for periplasmic expression 
of MBP-4xGlycTag; Amp 
Arabinose inducible expression vector for ClyA with a 
GlycTag. 
[95] 
 
[95] 
-pACYC-pgl  low copy number plasmid containing C. jejuni pgl operon; 
Chl 
[8] 
-pACYC-pgl::pglB  low copy number plasmid containing C. jejuni pgl operon 
with a knockout of pglB; Chl 
[8] 
-pMAF10-PglB  arabinose inducible expression vector for C. jejuni PglB; 
Tmp 
[10] 
-pMAF10-PglB** 
 
-pSN28-PglB 
 arabinose inducible expression vector for the catalytically 
inactive C. jejuni PglBD54NE316Q; Tmp 
IPTG inducible expression vector PglB purification; Spec 
[96] 
 
[12] 
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CHAPTER 4  
POLY-N-ACETYLGLUCOSAMINE DECORATED OMVS AS VACCINES  
 
Introduction 
 Poly-β-1,6-N-acetylglucosamine (PNAG) is a linear polysaccharide that is present on the 
surface of a wide range of human microbial pathogens [97]. In bacteria, it plays an important 
role in biofilm formation and host colonization [98-102]. The production of PNAG in bacteria is 
fairly well understood as there are homologous gene clusters responsible for its biosynthesis.  
The gene clusters, usually referred to as intercellular clusters of adhesion (ica in Pseudomonas 
aeruginosa and Staphylococcus aureus) or PNAG synthesis clusters (pga in E. coli), contain four 
genes which in E. coli are named pgaA,B,C,D. [98-100]. The genes pgaC and pgaD code for 
proteins associated with the inner membrane and use UDP-GlcNAc as a substrate to synthesize 
PNAG in the periplasm. Subsequently, pgaA and pgaB are associated with the outer membrane 
in Gram-negative bacteria or the outer face of the cytoplasmic membrane in Gram-positive 
bacteria and facilitate PNAG secretion and de-acetylation, respectively.  
 PNAG has been used in a variety of immunization and challenge models with varying 
degrees of success [97, 103-108]. It has been shown that antibodies capable of binding to both 
acetylated and de-acetylated forms of PNAG can be used to passively immunize animals against 
pathogens displaying PNAG [97, 107]. Additionally, it has been shown that the de-acetylated 
form of PNAG is the crucial antigen for generating a protective immune response. In this 
chapter, I will present a different path to formulating PNAG in a vaccination trial by presenting 
it on OMVs. Production of the polysaccharide PNAG was facilitated in hypervesiculating strains 
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of E. coli through overexpression of the genes in the PNAG biosynthetic pathway. In order to 
enrich the PNAG on our OMVs with the acetylated form, we also heterologously expressed the 
S. aureus PNAG deacetylase icaB in cells producing PNAG OMVs[109].   
 Mice were used as model organisms to evaluate the immunological response to PNAG 
on OMVs as a protective antigen.  After immunization of mice, the humoral immune responses 
to the PNAG OMVs was analyzed by quantifying the present of PNAG specific antibodies in the 
mice sera.  Immunized mice were then challenged I.V. with 10xmLD50 of S. aureus, and it was 
observed that PNAG OMVs provided partial protection. Lastly, to demonstrate that the humoral 
immune response to PNAG OMVs might be protective against a wider range of pathogens, we 
performed in vitro serum bactericidal assays against F. tularensis LVS.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Production of PNAG OMVs. Through overexpression of the pgaABCD in a hypervesiculating 
strain of E. coli, we will produce PNAG decorated OMVs. By also expressing the S. aureus deacetylase 
IcaB in the periplasm of these cells, we will create PNAG OMVs with a shift of the PNAG polymer toward 
the deacetylated form. We will also take advantage of the recombinant E. coli platform by producing 
OMVs from a strain with penta-acylated lipid A, greatly reducing the reactogenicity of the OMVs.   
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Results  
Production of PNAG can be augmented in E. coli. We first demonstrate that production of 
PNAG could be enhanced via addition of exogenous copies of the pga operon and that the 
produced PNAG is associated with OMVs.  For production of OMVs, we use the E. coli strain 
JC8031, a hypervesiculating strain that contains knockouts of tolR and tolA [85]. For augmented 
production of PNAG, the IPTG inducible plasmid pUc18TcP-pgaABCD (ppgaABCD) containing 
the PNAG biosynthetic operon from E. coli K1 was graciously provided by Gerald Pier. OMVs 
were harvested from the strain with induced ppgaABCD and Western blot analysis showed 
there was a corresponding increase of PNAG on OMVs (Figure 4.2a). We also observed the 
variable degree of polymerization of PNAG, with polymers ranging from approximately 37kDa 
to 150kDa (Figure 4.2a).  These molecular weights correspond to roughly 100 to 500 GlcNAc 
repeats. We further created the strain JC8031ΔpgaC containing an additional knockout of pgaC, 
the first gene in the biosynthetic pathway for PNAG.  This strain serves as a negative control for 
endogenous PNAG production.  The knockout was transduced into JC8031 through P1 phage 
from the corresponding strain in the Keio collection [93]. The relative abundance of PNAG in 
OMVs produced by the knockout, wild-type, and augmented strains was compared via PNAG 
specific dot blotting (Figure 4.2b). It can be seen from the intensities that knocking out pgaC 
had no effect on the dot intensity, indicating that there is some nonspecific binding (Figure 4.2b 
first lane). Treatment of the OMVs with Dispersin B, a very specific hydrolase that degrades the 
β-1-6 glycosidic bond in PNAG, showed a reduction in dot intensity to background, indicating 
that the PNAG being detected is authentic and that it is localized to the outer surface of OMVs 
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(Figure 4.2c). If the PNAG was lumenal, we would expect to see little to no degradation by 
Dispersin B.  
 
 
 
 
 
 
Figure 4.2: Characterization of PNAG on OMVs. OMVs from strains (JC8031 ±ΔpgaC ±ppgaABCD) were 
subjected to SDS-PAGE and Western blotting (a) or diluted in PBS according to shown dilution scheme 
(1:1 is 2mg/mL) and spotted on nitrocellulose membranes (b,c). The middle panel (b) shows relative 
signal from F598 PNAG binding antibody between negative control, wild type, and overexpressed PNAG 
pathways. In the right panel (c), OMVs were treated with Dispersin B before being dot blotted, reducing 
the signal from PNAG specific binding.  
PNAG is present on the exterior of OMVs. TEM imaging of uranyl acetate stained OMVs 
produced from JC8031ΔpgaC, JC8031, and JC8031 + ppgaABCD showed that the overall size and 
morphology of OMVs was unchanged by the presence of PNAG. There is an interesting 
observation of a biofilm-like material in OMVs produced from JC8031 + ppgaABCD that is likely 
the result of gelling properties of PNAG at higher concentrations (Figure4.3c). To visualize the 
PNAG directly on the surface of OMVs, we performed immunostaining on OMVs produced from 
JC8031ΔpgaC and JC8031 + ppgaABCD using the human monoclonal F598 and gold particle 
conjugated anti-human secondary (Figure4.3d). We were unable to visualize both the 
membrane and gold particles simultaneously, so OMVs only appear as a faint shadow on the 
transmission electron microgram. Cluster of the gold conjugated antibodies were observed in 
48 
 
circular patterns consistent with the diameters of OMVs in JC8031 + ppgaABCD samples. We 
did not observe similar trends in the JC8031ΔnlpI samples (Data not shown).      
 
 
 
 
 
 
 
 
 
 
 
 
PNAG physically associated with OMVs. PNAG OMVs were subjected to density gradient 
ultracentrifugation to determine if PNAG remained OMV associated (Figure 4.4).  During 
density gradient ultracentrifugation, macromolecules and particles migrate through a density 
gradient until buoyancy and sedimentation force reach an equilibrium. Liposomal nanoparticles 
like OMVs tend to be less dense than soluble macromolecules like proteins and polysaccharides 
due to their lipid content. By separating the PNAG OMV preparations by density, we showed 
that total protein content (Figure4.4a), PNAG content (Figure4.4b), and OmpA, an OMV specific 
protein marker (Figure4.4c) are all co-localized.  
Figure 4.3: TEM of PNAG OMVs. OMVs produced by JC8031ΔpgaC (a), JC8031 (b), or JC8031 +ppgaABCD 
(c,d) were visualized by TEM. The lipid bilayers of OMVs were observed via staining with uranyl acetate 
(a-c). Some islands of biofilm formation can also be seen when ppgaABCD is overexpressed  (c). PNAG 
OMVs were also subjected to immunostaining with F598 and subsequent visualization with gold-
conjugated anti-human secondary (d). The total protein concentration of OMVs used in a-c is 100µg/mL 
while 10µg/mL was used for d. Scale bars represent 200nm for a-c and 100nm for d.  
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Figure 4.4: Density gradient ultracentrifugation of PNAG OMVs. OMVs from JC8031 cells with induced 
ppgaABCD were harvested an approximately 1mg of OMVs was subjected to density gradient 
ultracentrifugation using an Optiprep gradient.  Discrete 0.5mL fractions were taken, and 10μL of each 
fraction was subjected to SDS-PAGE and analyzed by Coomassie stain (a) or western blot with F598 (b) 
or anti-OmpA (c). Numbers correspond to relative fraction density with 1 being the least dense and 
“pre” being the un-fractionated control.  
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Expressing icaB and knocking out lpxM does not affect the quantity of PNAG on OMVs. In 
previous studies where animals with immunized with PNAG, it was found that antibodies 
specific the de-acetylated form were responsible for protection. To shift the balance of the 
PNAG on our OMVs more toward the de-acetylated form, we heterologously expressed the 
PNAG de-acetylase, icaB, from S. aureus in our strain. This particular de-acetylase was chosen 
because it is not anchored membrane anchored like PNAG de-acetylases from Gram-negative 
species (i.e. E. coli pgaB). Rather it is membrane associated through binding to 
peptidoglycan[110]. To facilitate IcaB's expression in E. coli, we removed its native secretion 
signal sequence and replaced it with a Sec secretion sequence suitable for periplasmic 
expression in E. coli and added a C-terminal His6 tag for ease of detection. Western blotting of 
both periplasmic and whole cell fraction of JC8031 expressing IcaB showed it was present as a 
soluble protein in the periplasm and that the majority of it was associated with the membrane 
containing whole cell fraction (Figure4.5a). In addition, we also modified the OMVs produced 
by our cells to be less toxic by knocking out lpxM, an acyl transferase that is responsible for fully 
assembling the sixth and final acyl chain onto Lipid A. It has been shown by the DeLisa Research 
Group and others that this modification of lipid A drastically reduces its reactogenicity, making 
OMVs that contain this modified lipid A more suitable for use in vaccination trials. Using PNAG 
specific dot blotting, we have shown that expression of icaB, knockout of lpxM, and a 
combination of those two modifications does not affect the abundance of PNAG on OMVs 
(Figure4.5b).   
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Mice vaccinated with PNAG OMVs produce glycan specific antibodies. Two immunization trials 
were performed on four-week-old female BALB/c mice to quantify the humoral immune 
response to different PNAG OMV formulations (Figures 4.6,4.7). As expected, PNAG specific IgG 
titers observed form mice immunized with polysaccharide alone (dPNAG) or OMVs from cells 
without ppgaABCD were not significantly higher than titers observed from negative control 
groups (PBS). During both rounds of immunization, it is easy to see that PNAG specific IgG titers 
increased over time and after multiple rounds of booster immunizations (Figure 4.6). During 
both trials, PNAG + IcaB OMVs produced the highest glycan specific antibody titers among OMV 
immunization groups. Those titers were significantly higher than the titers observed for empty 
OMVs in all cases (p<0.05). During the second trial, we found that knocking out lpxM had no 
significant effect on PNAG specific IgG titers (Figure 4.6b). An inconsistency between the two 
Figure 3: Expression of icaB and knockout of lpxM does not affect PNAG on OMVs. The expression of 
periplasmic and whole cell fractions of IcaB from JC8031 cells was visualized using anti-His via Western 
blotting (a). PNAG on OMVs from the listed strains (JC8031±ΔpgaC±ΔlpxM ±ppgaABCD±icaB) were 
visualized with F598 and anti-human secondary via dot blotting (b).  
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rounds of immunization are the PNAG specific titers produced from mice immunized with the 
tetanus toxoid dPNAG oligomer. During the first trial, no mice showed any detectable anti-
PNAG IgG while during the second trial, every mouse showed and PNAG specific IgG titer higher 
than the highest OMV case. We attribute this difference to possibility of variance in the 
production of tetanus toxoid glycoconjugate. We also compared the PNAG specific titers of 
other antibody subtypes in a subset of mice from each trial (Figure 4.7). The IgA antibody titers 
from the first trial were predictably low as circulating IgA concentration in the blood is known 
to be quite low when compared to the concentration of IgA in mucosal membranes, but the 
highest titers were from the group immunized with PNAG + IcaB OMVs (Figure 4.7a). The IgM 
titers from the first trial closely followed the trends for the IgG titers, with the exception that 
there was no difference between the PNAG OMVs and PNAG IcaB OMVs (Figure 4.7b). This 
result is not completely unexpected as IgMs have much broader binding capabilities than 
affinity matured IgGs. We examined the titers of IgG1 and IgG2a from every group in the first 
immunization and form a subset in the second immunization (Figure 4.7c,d). We found that the 
titers from OMV immunized groups followed the trends of total IgG titers and that there was no 
significant bias for one IgG subtype over another. The only significant bias was observed during 
the second immunization when mice immunized with the tetanus toxoid glycoconjugate 
showed an apparent IgG1 bias (Figure 4.7d). 
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a 
b 
Figure 4: PNAG specific IgGs in mice immunized with PNAG OMVs. PNAG specific IgG titers from mice 
immunized with OMVs, tetanus toxoid glycoconjugate (TT+dPNAG), or dPNAG alone (dPNAG) 8 weeks 
after initial immunization. All OMVs were made in JC8031ΔpgaC background with two groups including 
the additional ΔlpxM knockout (b far right). Bars show the average + standard deviation of IgG titers in 
each group eight mice. The top panel (a) shows the titer results from the first round of OMV 
immunization while the bottom panel (b) shows the results from the second round. Mice immunized 
with OMVs were injected s.c. at t=0 and boosted at 3 and 6 weeks with 10µg total protein. Mice 
immunized with dPNAG were injected s.c. at t=0 and boosted at 3 and 6 weeks with 10µg dPNAG. Mice 
immunized with TT+dPNAG were injected s.c. at t=0 and boosted at 3 weeks with 10µg TT+dPNAG as 
measured by total protein content. The dPNAG and TT+dPNAG were administered with incomplete 
Freund's adjuvant. (*) and (**) represent statistical significance (p<0.05, p<0.01, respectively) by Tukey-
Kramer HSD.  
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PNAG OMVs provide partial protection against S. aureus challenge in mice. Groups of 
Immunized mice (n=8) were challenged with ten times the modified LD50 of S. aureus 
Figure4.7: Antibody subtype titers in mice immunized with PNAG OMVs. PNAG specific IgA (a), IgM (b), 
IgG1, and IgG2a (c,d) antibody subtype titers from mice immunized with OMVs, tetanus toxoid 
glycoconjugate (TT+dPNAG), or dPNAG alone (dPNAG) at week 7 (a,b) or week 8 (c,d) after initial 
immunization. All OMVs were made in JC8031ΔpgaC background with two groups including the 
additional ΔlpxM knockout (d far right). Bars show the average + standard deviation of subtype titers in 
each group of eight mice. The first three panels (a-c) show the titer results from the first round of OMV 
immunization while the last panel (d) shows the results from the second round. Mice immunized with 
OMVs were injected s.c. at t=0 and boosted at 3 and 6 weeks with 10µg total protein. Mice immunized 
with dPNAG were injected s.c. at t=0 and boosted at 3 and 6 weeks with 10µg dPNAG. Mice immunized 
with TT+dPNAG were injected s.c. at t=0 and boosted at 3 weeks with 10µg TT+dPNAG as measured by 
total protein content. The dPNAG and TT+dPNAG were administered with incomplete Freund's adjuvant. 
The only significant bias (p<0.05) in subtype titers was identified for mice immunized with TT+dPNAG 
between IgG1 and IgG2a during the second immunization (d, first group) as determined by Student's T-
test.  
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(Rosenbach ATCC 29213) via tail vein injection. At this dose, we expected to see no survivors in 
mice immunized with PBS, little to no protection in mice immunized with dPNAG alone or with 
any of the empty OMVs, and substantial to complete protection in mice immunized with the 
tetanus toxoid glycoconjugate or PNAG OMVs. Our observations when combining data from the 
two challenge experiments were consistent with our predictions. Mice immunized with PBS and 
empty *lpxM OMVs had the lowest survival rates (<20%) while those immunized with dPNAG 
alone, empty OMVs, and PNAG OMVs had an intermediate level of survival (38%). Mice 
immunized PNAG+IcaB OMVs, PNAG+IcaB *lpxM OMVs had the highest survival rate (50%) and 
were higher than the survival rate of the tetanus toxoid glycoconjugate positive control (42%) 
(Table 4.3). When comparing the Kaplan-Meyer survival curves of the individual groups in the 
first trial, we found that only PNAG+IcaB OMVs and TT+dPNAG provided significant (p<0.05) 
protection based on a log-rank score when compared to the PBS control (Figure 4.8a, Table 
4.1). In the second trial, PNAG OMVs and PNAG + IcaB *LpxM OMVs provided significant 
protection compared to the PBS control (p<0.05) while PNAG + IcaB OMVs were close to 
achieving significant protection (p≈0.08) (Figure 4.8b, Table 4.2). It should be noted that 
survival rates of mice in groups immunized with TT+dPNAG was very different between the two 
trials (50% vs. 25% Table 4.1,4.2) and that the PNAG specific IgG titers were inversely related in 
the two studies (<10^3 vs. >10^5 Figure 4.6). Interestingly, mice immunized with empty OMVs 
had a different survival rate (38% survival Table 4.1) than mice immunized with empty*lpxM 
OMVs (12.5% survival Table 4.2) while mice immunized with PNAG+IcaB OMVs showed the 
same survival rate as those immunized with PNAG+IcaB*lpxM OMVs (50% Table 4.3). 
Additionally, expression of IcaB may have impacted survival rates as PNAG OMV 
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 immunized mice survived at a rate of 38% and PNAG+IcaB OMV immunized mice had a survival 
rate of 50% (Table 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: PNAG OMVs provide partial protection against challenge with S. aureus. Groups of mice (n=8 
for except TT+dPNAG in b where n=4) were immunized with various OMV formulations and challenged 
with 10xmLD50 of S. aureus (strain Rosenbach ATCC 29213;2*10^8 CFU/100μL) via tail vein injection. Mice 
were weighed thrice daily for the first 72 hours then once daily for the remain 4 days. Mice were 
euthanized if their weight dropped below 80% of weight at t=0 or if they became moribund.  Mice 
immunized with OMVs were injected s.c. at t=0 and boosted at 3 and 6 weeks with 10µg total protein. 
Mice immunized with dPNAG were injected s.c. at t=0 and boosted at 3 and 6 weeks with 10µg dPNAG. 
Mice immunized with TT+dPNAG were injected s.c. at t=0 and boosted at 3 and 6 weeks with 10µg 
TT+dPNAG as measured by total protein content. The dPNAG and TT+dPNAG were administered with 
incomplete Freund's adjuvant. PNAG + IcaB OMVs and PNAG + IcaB *LpxM OMVs showed a significant 
protection in both challenges over PBS (p<0.05) groups as measured by a log-rank test.  
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Table 4.1: Survival data for first challenge experiment  
1Significant protection over mice immunized with PBS (p<0.05, log-rank test) 
**Administered with incomplete Freund's adjuvant 
 
Table4.2: Survival data for second challenge experiment 
1Significant protection over mice immunized with PBS (p<0.05, log-rank test) 
**Administered with incomplete Freund's adjuvant 
 
Table4.3: Combined endpoint survival rates 
mouse immunization groups # of survivors # of total mice % survival 
PBS 3 16 18.8 
TT+dPNAG** 5 12 41.7 
dPNAG** 3 8 37.5 
Empty OMVs 3 8 37.5 
PNAG OMVs 6 16 37.5 
PNAG IcaB OMVs 8 16 50.0 
Empty *lpxM OMVs 1 8 12.5 
PNAG + IcaB *lpxM OMVs 4 8 50.0 
**Administered with incomplete Freund's adjuvant 
 
 
mouse immunization group 
# of surviving mice at each day 
% survival 
0 1 2 3 4 5 6 7 
PBS 8 3 2 1 1 1 1 1 12.5 
TT+dPNAG** 8 4 4 4 4 4 4 4 50.01 
dPNAG** 8 5 5 5 5 5 3 3 37.5 
Empty OMVs 8 5 3 3 3 3 3 3 37.5 
PNAG OMVs 8 4 3 3 3 3 2 2 25.0 
PNAG IcaB OMVs 8 6 5 5 5 5 5 5 62.51 
mouse immunization group 
# of surviving mice at each day % survival 
0 1.5 2 2.625 3.125 5.125 7.125 
 
 
PBS 8 3 3 3 2 2 2  25.0 
TT+dPNAG** 4 2 2 1 1 1 1  25.0 
PNAG OMVs 8 5 5 4 4 4 4  50.01 
PNAG IcaB OMVs 8 4 4 4 3 3 3  37.5 
Empty *lpxM OMVs 8 2 1 1 1 1 1  12.5 
PNAG + IcaB *lpxM OMVs1 8 6 5 5 4 4 4  50.01 
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Antibodies produced in PNAG OMV vaccinated mice show bactericidal activity against F. 
tularensis. To determine if sera harvest from mice immunized with PNAG OMVs contained 
antibodies with bactericidal activity against other bacterial species, we performed serum 
bactericidal assays (SBAs) using F. tularensis LVS. Our results show that sera from mice 
immunized with PNAG+IcaB OMVs had a concentration dependent bactericidal activity that is 
higher than sera from mice immunized with PBS and that the highest concentration of sera had 
killing activity equivalent to that of the positive control F598 (Figure 4.9). Interestingly, sera 
from PNAG+IcaB immunized mice also showed higher bactericidal activity than sera from mice 
immunized with empty OMVs at lower serum concentrations (1/270,1/90), but that difference 
is greatly reduced at higher serum concentrations (1/30,1/10). Lastly, the serum from mice 
immunized with TT+dPNAG had a highly variable bactericidal activity with two mice's sera 
showing effectively no bactericidal activity and two others’ showing complete killing at all 
concentrations.  
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Figure 4.9: Serum bactericidal assay against F. tularensis LVS using serum from PNAG immunized mice. 
Data above shows percent LVS killed in SBA relative to killing by baby rabbit complement alone. Various 
dilutions of sera samples were used to show concentration dependent effects. The human monoclonal 
F598 was used as a positive control for bactericidal activity and was also diluted according to shown 
dilution scheme with 1:1 being equivalent to 1mg/mL. Values shown are averages of technical duplicates 
and biological replicates within immunization groups. The number of mice in each group are PBS n=1, 
TT+dPNAG n=4, Empty OMVs n=2, PNAG + IcaB OMVs n=8, and F598 monoclonal antibody n=1. Vertical 
bars represent the average bactericidal activity of sera samples within an immunization group. Error 
bars represent standard deviations of individual sera activities (TT+dPNAG, Empty OMVs, PNAG+IcaB 
OMVs) or range of technical duplicates of single samples (F598 and PBS).  
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Discussion  
 Here, we have shown that secreted, extracellular polysaccharide, PNAG, is enriched in 
OMV samples prepared from hypervesiculating strains and that amount of the polysaccharide 
can be augmented through overexpression of its native biosynthetic pathway. We have also 
shown through TEM that the lack of or overabundance of PNAG production does not affect the 
morphology of OMVs produced by the same cells. Though the presence of PNAG may form 
partially insoluble aggregates that contain OMVs, the entire samples remains in a colloidal 
suspension. Immunostaining of dilute OMV samples with gold nano-particles allowed us to 
visualize PNAG decorating OMVs, and density gradient ultracentrifugation showed that PNAG 
remains OMV associated even when the PNAG and OMV have different forces applied to them. 
Additionally, we showed that PNAG on OMVs is unaffected by the additional expression of a 
PNAG deacetylase from S. aureus (IcaB), the modification of the lipid A structure in the outer 
membrane via deletion of lpxM, and the combination of both these modifications. We have 
successfully created a non-canonical glycoconjugate OMV vaccine displaying PNAG through a 
wholly biosynthetic process.  
 We showed that our PNAG OMVs were able to elicit a strong PNAG specific IgG 
response in mice. This significant humoral immune response was consistent across two 
immunization trials. The antibodies produced by PNAG+IcaB OMVs were produced at a higher 
titer than PNAG specific antibodies produced by PNAG OMVs alone in both trials, though the 
difference was only significant in the first trial (p<0.05). The consistency of these responses is 
highlighted by the inconsistency of response to the tetanus toxoid glycoconjugate. Previous 
studies have shown that this glycoconjugate has produced significant anti-PNAG titers in mice, 
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but it's variability in our hands raises some concerns over how consistently immunogenic it is. 
We also showed that there was no significant difference in glycan specific IgG titers between 
mice immunized with PNAG+IcaB OMVs and mice immunized with PNAG+IcaB *lpxM OMVs, 
adding to the growing pool of data that this deletion does not affect the immunogenicity of 
OMVs but does reduce their reactogenicity. 
 The titers of glycan specific antibody subtypes (IgA, IgM, IgG1, and IgG2) followed the 
trends of total glycan specific IgGs in the round of immunization with the exception of IgM 
titers. There was no significant difference in PNAG specific IgM titers in mice immunized with 
PNAG OMVs and PNAG+IcaB OMVs. This result is not unexpected as IgMs tend to have a 
broader specificity than more mature subtypes and may not be able to distinguish the subtle 
difference between degrees of acetylation on PNAG polymers. The PNAG specific IgA titers are 
low as to be expected when examining IgA concentration in blood, but PNAG+IcaB OMVs do 
have the highest titer among immunization groups. The PNAG specific IgG1 and IgG2a response 
generated by OMVs in both immunizations show no bias for either subtype which is consistent 
with previous observations[111]. Conversely, we saw the expected significant bias for IgG1 in 
mice immunized with the tetanus toxoid glycoconjugate[106, 112]. A bias of IgG1 over IgG2a is 
representative of a Th2 immune response which tends to act more through the humoral route 
of adaptive immunity while an IgG2a over IgG1 bias implies a Th1 immune response which 
tends to act more through the cellular arm of the immune response. Protein glycoconjugates 
are known to produce a Th1 biased immune response while evidence is mounting that 
glycOMVs induce a more balanced hybrid Th1 and Th2 response[14-16]. The type of immune 
response generated by OMV vaccines is important as it can predict the effectiveness of the 
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vaccine against a particular pathogen. The pathogen S. aureus, for example, is successfully 
cleared through both responses[113, 114].  
 Our challenge experiments were showed significant protection against challenge with S. 
aureus when compared against PBS immunized mice. Mice immunized with PNAG+IcaB OMVs 
had the highest survival rate at 50%. In a result which maps directly back to IgG titers, the lpxM 
deletion did not affect the survival rates. Perhaps the most confusing and unexpected results 
are the inconsistencies between the trials vis-a-vis the TT+dPNAG immunization groups. In the 
first trial, mice immunized with TT+dPNAG generated no detectable glycan specific immune 
response among any of the antibody subtypes, yet the mice had a survival rate of 50% during 
the challenge. In the second trial, mice immunized with TT+dPNAG had the highest PNAG 
specific IgG titers recorded throughout the study, but only had a survival rate of 25%. These 
inconsistencies led us to investigate whether there was a correlation between antibody titers 
and survival in individual mice. After mapping survival data to PNAG specific titers, we saw no 
correlation between mice that survived and mice that had the highest IgG titers or individual 
mice that may have had a slight IgG1 vs. IgG2a subtype bias. This result implies that antibody 
titer alone is not a sufficient measurement for the success of a vaccine against S. aureus, and 
that the cellular immune response is also likely to be crucial to protection against S. aureus. This 
result was mirrored in our SBA against F. tularensis LVS. 
 As we previously discussed, though PNAG was first identified as a virulence factor in S. 
aureus, it present on a wide range of human pathogens[97, 115]. Our collaborator Gerald Pier 
has shown that PNAG is present on the surface of F. tularensis (unpublished), we have shown 
that a human monoclonal antibody against PNAG (F598) is able to completely kill F. tularensis 
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LVS in a SBA. We have also shown that sera from mice immunized with PNAG+IcaB OMVs also 
has complete bactericidal activity, albeit at higher concentration than the F598. Interestingly, 
sera from mice immunized with empty OMVs also showed bactericidal activity against F. 
tularensis LVS at higher concentrations. This result, combined with previously observed results 
from studies with glycOMVs, support the hypothesis that OMV chassis alone is able to provide a 
broad spectrum, non-specific, defense against pathogens. We hypothesize that the OMV 
chassis can serve to "prime" the immune response in an as yet uncharacterized manner, though 
our SBA experiments tend to suggest this non-specific priming is at least partially humoral. 
Similar the results observed from the survival data, individual IgG titers do not correlate with 
bactericidal activity. This lack of correlation is most dramatic when observing the bactericidal 
activity of sera from mice immunized with TT+dPNAG. All mice had exceptionally high PNAG 
specific IgG titers (>10^5), but sera from two of them showed almost no bactericidal activity. 
This observation further supports the conclusion that IgG titers alone are insufficient to predict 
the success or failure of a vaccine candidate.   
 Future immunization studies using PNAG OMVs against S. aureus should be conducted 
using larger immunization group sizes. As the measured difference between negative control 
(PBS immunized mice) and most positive experimental case (PNAG+IcaB OMVs) is relatively 
small in the context of this challenge model, yielding a hazard ratio of only 2.5. The initial 
experiment design assumed a hazard ratio of 18 which would have been the equivalent of 7/8 
mice surviving in the immunized groups and <1/8 mice surviving in the PBS groups. With the 
observed hazard ratio of approximately 2.5, we would need the sample size to increase to 
roughly 70 mice per group to achieve statistical significance[116]. Additionally, examining the 
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cellular response to PNAG OMVs would be valuable. By extracting splenocytes from immunized 
and naive mice, we could measure the production of cytokines such as IL4, IL8, and TNF-α in 
distinct subpopulations of cells in response to stimulation with PNAG alone, empty OMVs, and 
PNAG OMVs to elucidate how and which cells of the immune response may be responsible for 
the partial protection we have observed.  
 As PNAG is a prevalent on a wide variety of bacterial pathogens, we should test our 
current PNAG OMVs as vaccines against several other pathogens known to display PNAG on 
their surfaces. These pathogens could include several Gram-positive species such as 
Streptococcus pyogenes, Streptococcus pneumoniae, and Streptococcus agalactiae as well as 
Gram-negative species such as Salmonella enterica, Helicobacter pylori, or pathogenic strains of 
E. coli. In addition to further in vivo testing, we could more rapidly evaluate the protection using 
in vitro bactericidal assays and sera currently in stock from the second immunization trial. The 
first of these assays would be an opsonization and phagocytotic killing assay (OPKA) against S. 
aureus We would expect results from this assay to mirror what was seen during the challenge 
trial. We could then expand the range of pathogens rapidly using SBAs for the Gram-negative 
pathogens and OPKAs for the Gram-positives.  
 
Materials and Methods 
Bacterial strains and plasmids. The strains and plasmids used in this chapter are described 
below (Table4.4). Briefly strains are based on the well-known hypervesiculating strain JC8031 
whose phenotype is attributed a knockout of tolRA. Plasmid features are outlined below. The S. 
aureus PNAG deacetylase IcaB was amplified from genomic DNA and modified to contain a 
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DsbA signal sequence for periplasmic targeting and His tag for detection before being ligated in 
the pTrc99a expression vector.  The pathogenic strain of S. aureus used is the Rosenbach strain 
(ATCC 29213) and was cultured in liquid LB just as E. coli. It was, however, grown on high salt 
LBA (5% NaCl) which is selective against a broad range of possible contaminants. LVS was 
cultured in Modified Mueller Henton broth (MMH, Mueller Henton broth supplemented with 2% 
IsoVitaleX) overnight (closer to 24 hours) with shaking at 37˚C (Note: the key to liquid cultures of F. 
tularensis LVS is a high starting density). The saturated culture was then sub-cultured 1:50 in MMH and 
grown to mid-log phase (about 3 hours). Sealed 96-well plates were used to measure the OD600nm against 
MMH blank and the density determined using the previously described expression for CFU LVS per OD600 
per mL (4.9*10^6 CFU/mL/OD600). Bacteria were pelleted at 6,000xg for 5 minutes and washed with 
sterile PBS before being resuspended at a density of 105 CFU/mL in PBS for using the SBA.  
Creation of hypervesiculating PNAG knockout strains via P1 transduction. Briefly, donor 
phages were created by incubating P1 phage with the member of the Keio collection that 
contains the pgaC gene knocked out by a kanamycin resistance cassette[93]. After complete 
lysis of the donor culture, phage sample was clarified via centrifugation and stored at 4˚C until 
used. These phages were incubated with JC8031 and JC8031ΔlpxM for 30 minutes at 37˚C. Lysis 
of the recipient culture by phage was halted via the addition of 1mM sodium citrate before the 
cells were pelleted and plated on kanamycin and sodium citrate. Several colonies were 
restreaked on kanamycin and sodium citrate to verify removal of persistent phage. 
PNAG OMV preparation. OMVs were prepared as previously described in this work. Briefly, 
plasmids containing the necessary genes for production of PNAG and/or IcaB (Table 2.1) were 
transformed into appropriate hypervesiculating strains using electroporation. Transformed cells 
were selected on medium supplemented with the appropriate antibiotic. An overnight culture 
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of a single colony was selected and grown overnight in LB medium. Saturated overnights were 
subcultured 1:100 in LB supplemented with appropriate antibiotics. The cultures were grown to 
mid-log phase (OD600 ≈ 0.6) at which point, PNAG biosynthesis and IcaB expression were 
induced with IPTG (0.1 mM). Induction was allowed to proceed for 16-20 hours at 37˚C. Cells 
were pelleted via centrifugation at 10,000xg for 10 minutes. Cell-free culture supernatants 
were collected post induction and filtered through a 0.2 µm filter. Vesicles were isolated by 
ultracentrifugation (Beckman-Coulter; TiSW28 rotor; 141,000xg; 3 h; 4˚C) and resuspended in 
sterile PBS. OMVs were quantified by the bicinchoninic-acid total protein assay (BCA Protein 
Assay; Pierce) using BSA as the protein standard. 
Western and dot blotting. Whole cell and OMV samples were prepared for SDS-PAGE analysis 
by boiling for 15 min and cooling to room temperature in the presence of loading buffer 
containing β-mercaptoethanol. Samples were run on 10% cross-linked polyacrylamide gels 
(BioRad, MiniPROTEAN® TGX) and transferred to a PVDF membrane via semidry transfer. For 
dot blots, 5µL of untreated cells and OMVs were spotted directly onto nitrocellulose 
membrane.  After blocking with a 5% milk in Tris-buffered saline (TBS), membranes were 
probed with HRP-conjugated anti-His (Abcam) for the detection of IcaB in the periplasm. When 
analyzing samples for the presence of PNAG, membranes were first probed with the human 
monoclonal IgG F598 (graciously provided by Gerald Pier) and visualized with anti-human HRP-
conjugated secondary (Promega) [110]. When analyzing density gradient samples for OmpA, 
membranes with stained with mouse anti-OmpA (graciously provided by Wilfred Chen) before 
being visualized with anti-human HRP-conjugated secondary (Promega). Total protein in OMV 
fractions was visualized via non-specific protein stain (R250 BioRad). Signals were visualized 
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using HRP substrate Clarity ECL (BioRad) or white light transillumination and were imaged with 
a ChemiDoc XRS+ Imaging System (BioRad). 
Dispersin B treatment of PNAG OMVs. To further ensure that the observed signals from F598 
binding are caused by OMV associated PNAG, samples were subjected to enzymatic treatment with 
DispersinB.  DisperinB is an enzyme the very specifically degrades the β-1-6 glycosidic bond in PNAG and 
was purchased from Kane Biotech Inc [117]. The OMVs from JC8031 ±ppgaABCD were diluted to 
80μg/mL in PBS and treated with or without 50μg/mL DispersinB at 37⁰C for 24 hours. Samples were dot 
blotted similarly to those described previously [100]. 
TEM of PNAG OMVs. Electron microscopy. Structural analysis of vesicles was performed via 
transmission electron microscopy as previously described[13]. Briefly, vesicles were diluted to 
100µg/mL and negatively stained with 2% uranyl acetate and deposited on 400-mesh Formvar 
carbon-coated copper grids. Immunostaining of PNAG on OMV surfaces was performed as 
previously described[97]. Briefly, OMVs were diluted to 10µg/mL and deposited on 400-mesh 
Formvar carbon-coated copper grids. Deposited OMVs were then blocked with TBS containing 
5% BSA. Blocked grids were then incubated at room temperature F598, washed, and incubated 
with anti-human gold-nanoparticle-conjugated antihuman secondary (Sigma). Imaging of both 
types of samples was performed using a FEI Tecnai T-12 SPIRIT transmission electron 
microscope. 
Density gradient ultracentrifugation of PNAG OMVs. To ensure that the PNAG detected on 
OMVs was tightly bound, they were subjected to density gradient ultracentrifugation as 
previously described [88]. Briefly, OMVs were suspended in HEPES buffer (pH=6.8) instead of 
PBS and diluted into Optiprep solution to a final concentration of 1.0mg/mL in 1.5mL of 45% 
Optiprep solution in HEPES.  Discrete layers of Optiprep/HEPES were added to a 12mL 
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ultracentrifuge tube by carefully pipetting more dense layers below less dense layers.  Each 
layer was added in 330μL fractions with the following % composed of Optiprep: 10%, 15%, 20%, 
25%, 30%, 35%, 1.5mL OMV fraction containing 45% Optiprep, 9.0mL of 60% Optiprep to fill the 
tube.  The gradients were spun at 180,000xg for 3 hours after which thirteen 0.5mL fractions 
were taken from the top of the centrifuge tube.  The samples were subjected to SDS-PAGE and 
analyzed by Western blot for the presence of PNAG and OmpA. 
Preparation of PNAG. The purification of PNAG from E. coli was performed by modifying a 
combination of two previously described methods[103, 118]. The Top10 strain of E. coli which 
lacks endogenous production of PNAG, was transformed with ppgaABCD, and subcultured in LB 
containing tetracycline to mid-log phase. Production of PNAG was stimulated with IPTG and the 
cells were cultured for an additional 16 hours after which point they were pelleted via 
centrifugation at 10,000xg for 10 minutes. The supernatant was recovered and filtered through 
a 0.2µm filter before being concentrated 25x in a 3kda MWCO concentration column 
(Millipore). PNAG was then precipitated from solution via the addition of 2 volumes of 200 
proof ethanol. Insoluble PNAG was recovered by gentle centrifugation <1,000xg for <5min and 
the supernatant was discarded. The PNAG pelleted was partially resuspended in PBS (1:50 
original supernatant volume) and incubated overnight in 10µg/mL lysozyme and 10µg/mL 
DNAse I at 37˚C. The peptidoglycan and DNA digested PNAG was then subjected to 0.1mg/mL 
proteinase K treatment overnight at 37˚C. The isolated PNAG was then dialysed into water to 
remove digested peptides and nucleotides using a 5kDa Slide-a-lyzer cassette (Thermo) before 
being lyophilized.  To facilitate removal of acetyl groups from PNAG, it was resuspended in 5M 
NaOH and allowed to incubate overnight at 37˚C. The basic solution was then neutralized via 
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addition of an equal volume of 5M HCl, and the deacetylated PNAG was once again dialysed 
into water prior to a second lyophilization. The mass of recovered PNAG was quantified and 
used to make a 1mg/mL solution in PBS. The purity of this sample was evaluated using a 
Bradford total protein assay[119] as was determined to have <1% contaminating protein by 
mass.   
Determination of mLD50 for S. aureus via tail vein injection.  Due to ethical considerations, we 
have decided to use the modified LD50 (mLD50) for our challenge with S. aureus (Rosenbach 
ATCC29213). The mLD50 differs from the LD50 in that the disease is not allowed to progress to 
death. Mice are preemptively euthanized when they reach pre-selected clinical thresholds. We 
used weight loss (<80% initial weight) and moribundity as clinical end points for our trials. 
Though we do not know the mLD50 for this pathogen in this animal model, we expected it to be 
similar to previously reported LD50's for similar models[28, 120]. We therefore only used a small 
number of doses (10^6, 10^7, and 10^8 CFU/mL) and a small number of mice in each dosing 
group (n=8). Twelve-week-old female BALB/c mice were administered 200µL of each of the 
above doses via tail vein injection. We observed that at 10^8 CFU/mL, exactly 50% of the mice 
were unable to clear the infection, making it our putative mLD50. The protocol number for all 
animal trials performed in this work is (2012-0132) and was approved by the Institutional 
Animal Care and Use Committee at Cornell University.  
Mouse immunization and challenge with S. aureus. We performed a power analysis to 
determine the appropriate group size [116]. For this analysis, we assumed a Type I error rate of 
20%, implying a 1:5 chance of inappropriately evaluating a mouse as "protected". We assume a 
type II error rate of 5%, meaning we expected at most a 1:20 chance of inappropriately calling a 
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mouse "sick". We decided to dose the mice at 10xmLD50 to ensure a high hazard ratio, meaning 
we expected all the mice in unimmunized group to succumb to infection (only 5% survival). We 
expected survival rates of vaccinated mice to relatively high (90% survival). These assumptions 
yield a hazard ratio of 18. Based on these assumptions and immunization group sizes, we 
expected 47.5% of all mice to survive challenge.  
 A group size of n=8 mice was predicted to be sufficient for achieving significant 
protection in this challenge model. Four-week-old female BALB/c mice were immunized 
subcutaneously with 100µL injections of saline control (PBS), adjuvanted purified PNAG, 
adjuvanted tetanus toxoid conjugated to a pentamer of deacetylated PNAG (kindly provided by 
Gerald Pier), or one of the OMV formulations. Each dose represented 10µg of material as 
determined by total mass in the case of purified PNAG, and total protein content as determine 
by BCA in all other cases. Adjuvanted samples were formulated with incomplete Fruend's 
adjuvant (30% vol/vol) obtained from Sigma. Mice were boosted at 3 weeks and again at 6 
weeks with the same doses. Blood was collected from each mouse from their mandibular sinus 
immediately before initial immunization and every subsequent week during the first 
immunization trial. During the second immunization trial, blood was only collected prior to each 
immunization and challenge. Additionally, a subset of mice in the second trial were euthanized 
prior to challenge to obtain larger blood samples via cardiac puncture.  
 Immunized mice were challenged with 10xmLD50 (10^9 CFU/mL) in 200µL of sterile PBS. 
Mice were weighed prior to challenge to establish an intervention weight when we would 
euthanize them (<80% initial weight). Mice were observed thrice daily for the first 72 hours 
then once daily for the remainder of the trial. During the first 24 hours, most mice were 
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euthanized based on moribundicity or at the urging of Cornell Center for Animal Resources and 
Education (CARE) veterinary staff. After 36 hours, we began to euthanize mice whose weight 
loss indicated severe bacteremia.   
Enzyme-linked immunosorbent assay (ELISA) Glycan-specific antibodies produced in 
immunized mice were measured via indirect ELISA using a modification of a previously 
described protocol[13, 97, 106, 112]. Briefly, sera were isolated from the collected blood draws 
after centrifugation at 2,200xg for 10 min and stored at -20˚C. 96-well plates (Maxisorp; Nunc 
Nalgene) were coated with purified PNAG (25 μg/mL in PBS pH 7.4) and incubated overnight at 
4°C. All PBS used was at pH 7.4. The next day, plates were washed 3 times with PBST (PBS, 
0.05% Tween-20, 0.3% BSA) and blocked overnight at 4°C with 5% nonfat dry milk (Carnation) in 
PBS. Samples were serially diluted by a factor of five, in triplicate, between 1:100-1:7,812,500 in 
blocking buffer and added to the plate for 2 h at 37°C. Plates were washed 3 times with PBST 
and incubated for 1 h at 37°C in the presence of one of the following horseradish peroxidase-
conjugated antibodies depending on which antibody subtype was being assayed: goat anti-
mouse IgG (1:10,000; Abcam), anti-mouse IgG1 (1:10,000; Abcam), or anti-mouse IgG2a 
(1:10,000; Abcam), anti-mouse IgM (1:10,000; Abcam), or anti-mouse IgM (1:10,000; Abcam). 
After 3 additional washes with PBST, 3,3’-5,5’-tetramethylbenzidine substrate (1-Step Ultra 
TMB-ELISA; Thermo Scientific) was added and the plate was incubated at room temperature for 
30 min. The reaction was halted with 2M H2SO4. Absorbance was quantified via microplate 
spectrophotometer (Molecular Devices) at a wavelength of 450 nm. Serum antibody titers were 
determined by measuring the lowest dilution that resulted in signal three standard deviations 
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above background. Statistical significance was determined using Tukey-Kramer post-hoc honest 
significant difference test and compared against the empty OMV control cases. 
Serum bactericidal assay (SBA). The serum bactericidal assay was a modified version of 
previously reported protocols[97, 121, 122]. Previously aliquoted baby rabbit complement 
(Cedarlane) stored at -80˚C was used for this assay. An aliquot of heat inactivated complement 
(56˚C for 30 minutes) was also used as a control. Both active and inactive complement were 
thawed gently at room temperature and immediately placed on ice prior to use in the assay. 
For the experiment to determine optimal assay conditions, the complement concentration was 
varied in 1% increments from 0% to 10%. Serum samples from each mouse heat inactivated via 
incubation at 56˚C for 30 minutes prior to use. The human monoclonal F598 (1mg/mL) 
antibodies was used as positive controls for bactericidal activity. Serum was diluted 1:2 in 
sterile PBS and then serially diluted 1:3 three times to maximum dilution factor of 1:54 before 
being diluted 1:5 in the assay (final concentration range 1:10-1:270). The assay was performed 
in sterile 96-well plate in a biosafety cabinet. 
  For the optimization experiment, the assay began by adding 90µL of appropriately 
diluted baby rabbit complement or heat inactivated complement to each well.  Then, 10µL of 
105 CFU/mL F. tularensis LVS were added to each well. The plates were incubated at 37˚C with 
5% CO2 for 30 minutes. Every six minutes beginning at t=0, 10µL of each reaction was spotted 
on cysteine heart agar + 9% sheep's blood and allowed to trail down the half the length of the 
plate to facilitate colony counting. Plates were then incubated overnight at 37˚C with 5% CO2 
and colonies were counted the following day to determine optimal incubation time and 
complement concentration.  
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 The optimal conditions for the SBA were determined to be 6% BRC and 30 minutes’ 
incubation time. For each assay, 10µL of appropriately diluted serum was added to 6% BRC, 6% 
heat-inactivated BRC, or sterile PBS. To start the assay, 5µL of 105 CFU/mL F. tularensis LVS 
were added to each well. After 30 minutes incubating at 37°C with 5%CO2, 10µL of the reaction 
mixes were spotted on cysteine heart agar + 9% sheep's blood and allowed to trail down the 
half the length of the plate to facilitate colony counting. Plates were then incubated overnight 
at 37˚C with 5%CO2 and colonies were counted the following day to determine optimal 
incubation time and complement concentration. 
 
Table4.4: Bacterial strains and plasmids used in this chapter. 
Strain   Genotype  Source 
-S. aureus  Rosenbach  ATCC 29213 
-F. tularensis   LVS   Bradley Jones 
-JC8031  supE hsdS met gal lacY tonA ΔtolRA  [85] 
-JC8031ΔlpxM detoxified lipid A  [16] 
-JC8031ΔpgaC::kan no endogenous PNAG production with 
hypervesiculation; kan  
This study 
-JC8031ΔlpxMΔpgaC::kan no endogenous PNAG production with modified lipid A 
in a hypervesiculating strain; kan 
This study 
-Top10  strain lacking endogenous PNAG production  Thermo Fisher 
       
Plasmid  Description; Resistance marker   
pTrc99a IPTG inducible expression vector; Amp Lab stock 
ppgaABCD  IPTG inducible expression vector; Tc Gerald Pier  
pTrc99a-IcaB IPTG inducible expression vector for periplasmic 
expression of IcaB; Amp 
This study 
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CHAPTER 5  
DISCUSSION AND FUTURE DIRECTIONS 
Discussion 
 In this work, we have made significant progress toward the creation of novel 
glycoconjugate vaccine candidates as well detailing general methods which can be used to 
develop and even wider range of vaccine candidates. We have shown successful 
glycoengineering of E. coli on several different scales. First, through metabolic engineering of 
hexosamine metabolism, we were able to use a GlcNAc salvage pathway to make E. coli 
glycobiology compatible with well-characterized, bioorthogonal azide-phosphine chemistry. We 
were able to use this chemistry on live E. coli cells displaying azide-labeled lipid-linked glycans 
via fluorescence flow cytometry. Next, we created a glycoengineered hypervesiculating strain 
that was able to produce vesicles loaded with lumenal glycoproteins containing the F. tularensis 
O-antigen. Though these glycoprotein containing OMVs are suitable vaccine candidates for F. 
tularensis, they contained mostly short oligomers of O-antigen subunits. To overcome this 
limitation, we also developed a method for conjugating full-length O-antigen oligomers to ClyA 
via in vitro protein glycosylation. Glycoprotein containing OMVs produced through either 
method are intact liposomes and suitable for use in immunization trials.   
 We also glycoengineered E. coli to produce a non-canonical glycoconjugate OMV 
vaccine through the overexpression of the PNAG biosynthesis pathway in a hypervesiculating 
strain.  We showed that the morphology of OMVs produced from such a strain are unaffected, 
and that PNAG is localized to the surface of those OMVs. It was known that PNAG was both 
secreted into the culture media E. coli and that some fraction remained bound to the outer 
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surface of cells, but we were the first to show that it is also associated with OMVs. We also 
showed via density gradient ultracentrifugation that this physical association is strong enough 
to resist separation by different drag and buoyant forces. In preparation for using these PNAG 
OMVs in an animal model, we further modified them by producing them in strains expressing a 
PNAG deacetylase from S. aureus and by knocking out an acyltransferase to make the OMVs 
less reactogenic. These modifications had no impact on the amount of PNAG displayed on the 
OMVs. The PNAG+IcaB*lpxM OMVs were able to produce a PNAG specific IgG humoral immune 
response and were provided better protection against S. aureus than mice immunized with an 
adjuvanted tetanus toxoid PNAG glycoconjugate. We also showed that sera from mice 
immunized with PNAG+IcaB OMVs had bactericidal activity against and attenuated strain of F. 
tularensis. This bactericidal activity against two vastly different bacterial pathogens speaks to 
the possibility of using PNAG+IcaB OMVs as a single subunit vaccine against multiple pathogens.  
 As mentioned previously in this work, there is no current satisfactory explanation for the 
glycan specific immune responses generated by immunization with glycOMVs such as the PNAG 
OMVs used herein[15, 16]. This uncertainty stems from the fact that polysaccharides are 
generally T-cell independent antigens. Except for a specific case involving a zwitterionic 
polysaccharide, carbohydrate antigens are generally not displayed on MHCII by professional 
antigen presenting cells. Our current hypothetical model for how the adaptive immune system 
responds to polysaccharides on OMVs is inspired by the current model for the generation of 
glycan specific antibodies in response to protein glycoconjugates. In this model, a naive B-cell 
with a glycan specific BCR binds the glycan component of the glycoprotein and subsequently 
endocytoses the entire molecule. As a professional antigen presenting cell, the B-cell digests 
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the glycoprotein and loads peptide fragments onto MHCII where they are presented to naive T-
cells which may have a TCR that binds the displayed peptide, resulting in the formation of an 
immune synapse. An important point to note here is that the displayed peptide need not 
contain the glycan to form a successful synapse. Indeed, due to size limitations of the MHCII 
binding cleft, it is likely that the peptide responsible for the immune synapse is from a portion 
of the protein that does not contain the glycan[36]. It is possible for a glycOMV to stimulate the 
formation of immune synapses in the same way.  
 The glycOMV is a liposome nano-particle, ranging in diameter from 50nm to 250nm or 
larger. The smaller end of this size range (<100nm), which represents the majority of the 
glycOMVs, is well within the endocytotic capability of a professional APCs such as a naive B-
cell[123]. If a naive B-cell with glycan specific BCR encounters a cognate glycOMV, the BCR will 
oligomerize causing subsequent endocytosis of the entire glycOMV nanoparticle. As a 
professional APC, the B-cell will digest and process the OMV as well as all of its endogenous 
protein cargo. As there are many proteins found in OMVs that have strong TCR binding 
epitopes, forming an immune synapse with a T-cell should be guaranteed[14]. It is through this 
co-localization of BCR epitope (the glycan) and TCR epitopes (endogenous OMV proteins) that 
we hypothesize glycOMVs are able to generate glycan specific antibodies. In this way, 
glycOMVs must be intact liposomes as simply mixing the carbohydrate antigen of interest with 
OMVs would not guarantee co-delivery to the same naive B-cell.  
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Future Directions  
Use of Azide-linked sugars on OMVs to create small molecule conjugates. By creating OMVs 
displaying azide-linked glycans, we can functionalize OMVs so that any antigen of interest can 
be attached to them. By also using OMVs without azide-linked glycans on their surface as a 
control in immunization experiments, we could then have two samples: one sample in which 
co-delivery is guaranteed by bioorthogonal chemistry between the antigen of interest and azide 
labeled glycans and a second sample where the antigen of interest is not co-delivered with 
OMV antigens. This second sample controls for the innate immunostimulation caused by OMVs. 
This approach could be used directly with PNAG OMVs engineered to use the GlcNAZ 
compatible salvage pathway discussed in Chapter 1. As UDP-GlcNAc is the substrate used for 
PNAG biosynthesis, by overexpressing only pgaACD along with the GlcNAZ salvage pathway, we 
could produce fully acetylated PNAG on OMVs. We expect that by feeding these cells 
Ac4GlcNAz, we will optimize the amount of azide present on the surface of OMVs. One 
application for this approach is the development of vaccines against addictive drugs.  
 From as early as the 1970's, researchers have been attempting to create vaccines 
against addictive drugs such as caffeine, morphine, cocaine, and methamphetamine[124-129]. 
The approaches taken in these studies have been similar to those taken by researchers 
developing glycoconjugate vaccines in that they have been chemically conjugating these small 
molecule drugs to strongly immunogenic proteins such as cholera toxin B[130], EPA[131], and 
OmpC from N. meningitidis[126]. More modern approaches have used protein-based 
nanoparticles as carrier proteins including adenovirus[129] and peptide nanofibers[127].  
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 One study compared the immune response to methamphetamine (MA) conjugated to 
ovalbumin (OVA), keyhole limpet hemocyanin (KLH), tetanus toxoid (TT), and OmpC[126].  In 
the study, they found that MA specific IgG titers were highest in mice immunized with the MA-
OmpC glycoconjugate. The researchers hypothesized that this may be due to residual LPS that is 
co-purified with OmpC[132]. Looking back with the knowledge of OMV biology and armed with 
the co-delivery hypothesis, we hypothesize that these researchers were actually immunizing 
mice with MA conjugated to OmpC embedded in OMVs from N. meningitidis.  
 The researchers tested their hypothesis by adding the LPS mimic monophosphorlyated 
lipid A (MPL) to the other MA protein conjugates. The new formulations with the MPL adjuvant 
showed an increased MA specific IgG response relative to non-MPL adjuvanted samples, 
indicating the innate immunostimulatory properties of LPS in OMVs played a role in the success 
of the MA-OmpC conjugate. However, the MPL formulated protein conjugates still showed 
significantly lower MA specific titers than the MA-OmpC conjugates. The proposed method of 
functionalizing azide-linked PNAG OMVs is ideal for an immunization trial using one of these 
small molecule drugs. The drugs are relatively easy to synthesize and are amenable to 
functionalization by bioorthogonal chemistry reactive groups. Immunization of mice would 
allow us to test the hypothesis of cocaine and carbohydrate antigen co-delivery (CocaCoDe) 
which implies that conjugation to the OMV liposome is crucial for the most effective 
immunostimulatory effect while also creating a novel vaccine candidate against an addictive 
drug.   
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Creation of multivalent OMV vaccines. While glycOMVs displaying the F. tularensis O-antigen 
are protective against lethal challenge with F. tularensis and we expect OMVs containing 
lumenal EPA glycosylated with F. tularensis O-antigen to at least as effective in a challenge 
model, it is possible that neither formulation will induce long term protection against F. 
tularensis. If that is the case, several protein antigens native to F. tularensis previously reported 
to have TCR binding epitopes (GroEL and IglB) could be modified to contain glycosylation sites 
[92].  These modified antigens can be used as lumenal or outer membrane protein carriers for 
the O-antigen in OMVs stimulating stronger protection against F. tularensis. It should also be 
possible to formulate glycOMVs decorated with both O-antigen and PNAG, providing a second 
glycan antigen that may provide additional protection against challenge. These formulations 
would be examples of multi-subunit OMV vaccines against a single pathogen. Alternatively, it 
should be possible to create multi-subunit vaccine against more than one pathogen. If 
glycOMVs displaying F. tularensis O-antigen are sufficiently protective against all strains over a 
long enough period of time, you could load a protein antigen from a second pathogen such as 
tetanus toxoid into the OMVs, creating a multivalent vaccine against two pathogens.   
 
Use of a twostep glycosylation process for site-specific glycosylation of a target protein with 
two unique glycans. It has been shown that it is possible to produce glycosylated proteins in 
vivo with near 100% glycosylation site occupancy when using C. jejuni PglB as the OST and its 
cognate optimal acceptor sequon DQNAT  [8, 24, 86].  Conversely, it was also shown that a 
modified sequon of AQNAT has very little to no detectable glycosylation when wild type C. 
jejuni PglB is used as the OST.  The DeLisa Research Group has engineered a mutant of C. jejuni 
80 
 
PglB (PglBLQ) with relaxed acceptor site specificities that can glycosylate both DQNAT and 
AQNAT sites [8, 86].  The availability of OSTs with different acceptor site preferences enables 
orthogonal glycosylation schemes.  Here we propose to leverage this system through creating 
an acceptor protein with two different glycosylation sites (DQNAT and AQNAT) and displaying it 
on OMVs. Under this regime, the DQNAT site can be glycosylated by both wild type PglB and 
PglBLQ while the AQNAT site is only able to be glycosylated by PglBLQ.  If wild type PglB was used 
in the cell producing OMVs and PglBLQ was used in an in vitro glycosylation reaction after the 
OMVs were harvest, it would be possible to create glycoproteins on OMVs with two distinct 
oligosaccharides at two distinct specific sites.  
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